Annotated References

Annotated References

• ABRUZZO GK, FLA1 ihRY AM, GILL CJ, SMITH JG, ICROPPH, BARTIZAL K: Evaluation of water soluble lipopeptides L-733,560, 1,705,589 and L-731,373 in a mouse model of disseminated aspergillosis. Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993 Abstr. 355. L-733,560 and L-705,589 but not L-731,373, significantly prolonged survival in a mouse disseminated aspergillosis model at 0.02 mg/kg 43, bid X5.
   Google Scholar
• ACTOR P, URI JV, ZAJAC L, GUARINI JR, PHILLIPS L, PITKIN DH, BERGES DA, DUNN GL, HOOVER JRE, WEISBACH J:SKF 75073, a new parenteral broad-spectrum cepha-losporin with high and prolonged serum levels. Antimi-crob. Agents Chemother. (1977) 13:784–790.
   Web of Science ®Google Scholar
• ADEFARATI AA, HENSENS OD, JONES ETT, TKACZ JS: Pneumocandins from Zalerion arboricola V. Glutamic acid- and leucine-derived amino adds in pneumo-candin Ao (L-671,329) and distinct origins of the substi-tuted proline residues in prieumocandins Ao and Bo. J. Antibiot. (1992) 45:1953–1957.
   Google Scholar
• Discusses the distinct biogenesis of the proline residues of pneumo-candin Ao and pneumocandin Bo.
   Google Scholar
• ADEFERATI AA, GIACOBBE RA, HENSENS OD, TKACZ JS: Biosynthesis of L-671,329, an echinocandin-type anti-biotic produced by Zalerion arboricola: Origins of some of the unusual amino acids and the di-methylmyristic acid side chain. J. Am. Chem. Soc. (1991) 113:3542–3545.
   Web of Science ®Google Scholar
• This biosynthetic investigation shows that the 3-hydroxy-4-methyl-proline is derived from leucine not proline. The unusual homotyros-Me is derived from tyrosine and acetate. Lastly, the methyl groups of the side chain come from methionine.
   Google Scholar
• ALBORN WEJ, FLOKOWITSCH JE, WU CYE, PRESTON DA, TERNANSKY RJ: Biological evaluation of a series of carbacephems showing broad-spectrum activity in-cluding methicllin-resistant Staphylococcus aureus (MRSA). 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 926.
   Google Scholar
• ALDRIDGE KE, GELFAND MS, SCHIRO DD, BARG NL: The rapid emergence of fluoroquinolone-methicillin-resis-tantStaphylococcus aureus infections in a community hospital Diagn. Microbiol. Infect. Dis. (1992) 15:601–608.
   PubMed Web of Science ®Google Scholar
• ANDRASSY K, KODERISH J, GEORGES K, SONNTAG H, HIRAUCHI K: Pharmacokinetics and hemostasis follow-ing administration of a new injectable oxacephem (6315 S, flumoxet) in volunteers and in patients with renal insufficieny. Infection (1991) 19 (Suppl. 5) S-S296–302.
   Google Scholar
• ANDREW JM, BASWELL F, WISE R: In vitro activity of RP 59500 against staphylococci and respiratory patho-gens. 33rd International Conference On Antimicrobial Agents and Chemotherapy New Orleans, US (1993): Abstr. 1044.
   Google Scholar
• ANDRIOLE VT: Pharmacokinetics of cephalosporins In patients with normal or reduced renal function. J. Infect Dis (1978) 137 (Suppl.) S–88–97.
   Google Scholar
• ANGEHRN P, HOHL P, HUBSCHWERLEN C, PAGE M, THEN It: Antibacterial properties of Ro 40–6890, a broad-spec-trum cephalosporin, and its novel orally absorbable ester, Ro 41–3399.
   Google Scholar
• Antimicrob. Agents Chemother. (1992) 36:2825–2834.
   Google Scholar
• Anonymous. World market for anti-infectives. Marketletter1993 November 9, 1993.
   Google Scholar
• ANTEUNIS MJO, CALLENS R, SHARMA NK: Carboxymethy-lation of keto substrates. A useful grafting procedure applied on virginiamycin factors A and B. Bull. Chem. Soc Chim. Beiges (1988) 97:209–217.
   Google Scholar
• ANTEUNIS MJO, VAN DER AUWERA, VANFLETEREN L, BORREMANS F: The synthesis of a Ny- phthalyl-Na - methyl-a-y dianninobutyryl congener of virginiamycin Si. Bull .Soc. Chim. Belges (1988) 97:135–148.
   Google Scholar
• APPELBAUM PC, SPANGLER SK, JACOBS MR: Susceptibility of 139 penicillin-susceptible and resistant isolates of Streptococcus pneumoniae to RP 59500, erythromycin, vancomycin, temafloxacin, ciprofloxacin and oflox-acin. 31st International Conference On Antimicrobial Agen Ls And Chemotherapy Chicago, (1991) Abstr. 893.
   Google Scholar
• APPLEBAUM PC: Antimicrobial resistance inStreptococ-cuspneumoniae: an overview. Clinical Infectious Diseases (1992) 15:77–83.
   PubMed Web of Science ®Google Scholar
• ARCHER G, AUGER P, DOERN G, FERRARO MJ, FUCHS P, seJORGENSEN J, LOW D, MURRAY P, RELLER LB, STRATTON C, WENNERSTEN, MOELLERING RC: RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci. Diagn. Microbiol. Infect. Dis.(1993) 16(3):223–226.
   PubMed Web of Science ®Google Scholar
• An important contribution to the evaluation of RP 59500
   Google Scholar
• ASADA K, SUZUKI E, KONDO N, KUWUHARA-ARAI K, HIRAMITSU K: In vitro antimicrobial activity of a newly synthesized oral cephem antibiotic, E1101. 33rd Inter-science Conference on Antimicrobial Agents and Chemother-apy New Orleans (1993) Abstr. 893.
   Google Scholar
• ASZODI J, BONNEFOY A, CHANTOT JF, FAVEAU P, D'AM-BRIERES SG, MAUVAIS P: Synthesis and antibacterial activity of a series of novel catechol-substitued vinylo-gous cephalosporins. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr, 890.
   Google Scholar
• ASZODI J, BONNET A, CHANTOT J-F, COSTEROUSSE G,TEUTSCH G: Synthesis and antibacterial activity of iso-cephems. In: Recent Advances in the Chemistry of5-Lactam Antibiotics: Bentley PH, Southgate R (Eds), The Royal Society of Chemistry, London, 1989 p350–364.
   Google Scholar
• ASZODI J, BONNET A, TEUTSCH G: Enantioselective synthesis of versatile 2- isocephem synthon. Tetrahedron (1990) 46:1579–1586.
   Web of Science ®Google Scholar
• ASZODI J, BONNET A, CHANTOT JF, COSTEROUSSE G, GOUIN D'AMBRIERE S, TEUTSCH G: Synthesis and in vitro antibacterial activity of a series of 1-dethia-2-thia-cephems (isocephems). 28th Intersci. Conf Antimicrob. Agent Chernother. Los Angeles 1988 Abstr. 435.
   Google Scholar
• AUCKENTHALER R, BAQUERO F, BRAVENY I, DORN- BUSCH K, DLTVAL J, FLEUREI 1E J, GEORGOPOULOS A,KAYSER FH, PRIVITERA G, ROHNER P, SITAVANC R, WIL-LIAMS JD: In vitro activity of RP 59500 against staphylo-cocci: European multicenter study. 31st International Conference On Antimicrobial Agents And Chemotherapy Chicago, (1991), Abstr. 900.
   Google Scholar
• AUMERCIER M, BOUHALLAB S, CAPMAU ML, LE GOFFIC F: RP59500: A proposed mechanism for its bactericidal activity. J. Antimicrob. Chemotber. (1992) 30 (Suppl. A):9–14.
   Google Scholar
• AWALD P, ZUGEL M, MONKS C, FROST D, SELITRENNIK- OFF CP: Purification of 1,34i-glucan synthase from Neurospora-crassa by product entrapment. Exper. My-col. (1993) 17:130-141. A highly purified fungal glucan synthase enzyme is reported.
   Google Scholar
• AXELROD J, TOMCHICK L. Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. (1958) 233:702–705.
   PubMed Web of Science ®Google Scholar
• AZOULAY-DUPUIS E, VALLEE E, VEBER B, POCIDALO JJ: Activity of RP 59500, a new semisynthetic strepto-gramin, in mouse pneumonia induced by a macrolide-resistant strain of Streptococcus pneumoniae. 31st In-ternational Conference On Antimicrobial Agents And Chemotherapy, (1991) Chicago, Abstr. 902.
   Google Scholar
• AZOULAY-DUPUIS E, VALLEE E, POCIDALO JJ: Efficacy of RP 59500, a new semlsynthetic streptogramin, against penicillin-resistant and muhiresistant strains of strep-tococcus pneumontae. 32nd International Conference On Antimicrobial Agents And Chemotherapy, Anaheim, (1992), Abstr. 1311.
   Google Scholar
• AZOULAY-DUPUIS E, et al.: In vivo efficacy of a newfluoroquinolone, sparfloxacin, against penicillin-sus-ceptible and -resistant and multiresistant strains of Streptococcus prieumontae in a mouse model of pneu-monia. Antimicrob. Agents Chemother. (1992) 36:2698–2703.
   Google Scholar
• BAILEY EM, KRAKOVSKY DJ, RYBAK MJ: The triazole antifungal agents: A review of itraconazole and flucona-zole. Pharmacother. (1990) 10:146–153.
   PubMed Web of Science ®Google Scholar
• BALKOVEC JM, BLACK RM: Reduction studies of antifun-gal echinocandin lipopeptides. One step conversion of echinocandin B to echinocandin C. Tetrahedron Lett. (1992) 33:4529–4532.
   Web of Science ®Google Scholar
• Describes selective reductions at the hemiaminal, and homotyrosine positions of the echinocandin and pneumocandin natural products.
   Google Scholar
• BALKOVEC JM, BLACK EM, HAMMOND ML, HECK JV, ZAMBIAS RA, ABRUZZO G, BARTIZAL K, KROPP H, TRAI-NOR C, SCHWARTZ RE, MCFADDEN DC, NOLLSTADT KH, PITTARELLI LA, FOWLES MA, SCHMATZ DM: Synthesis, stability, and biological evaluation of water-soluble prodrugs of a new echinocandin lipopeptide. Discov-ery of a potential clinical agent for the treatment of systemic cadidiasis and Pneumocystis carinii pneumo-nia (PCP). J. Med Chem. (1992) 35:194–198.
   Google Scholar
• Prodrugs of pneumocandin Bo (L-688,786) are described. The chemi-cally stable phosphate ester derivative, L-693,989, showed bio-equivalence to the parent compound in rodent models of candidiasis and PCP.
   Google Scholar
• BALKOVEC JM, BLACK EM, ABRUZZO GK, BARTIZAL K, DREIKOFtN S, NOLLSTADT K: Pneumocandin antifungal Ilpopeptides. The phenolic hydroxyl is required for 1,3-13-glucan synthesis inhibition. Bioorg. Med. Chem. Lett. (1993) 3:2039–2042.
   Google Scholar
• Removal of phenolic hydroxyl of homotyrosine residue of pneumo-candin Bo shows a 140-fold loss in glucan synthesis inhibition.
   Google Scholar
• BALL P: Emergent resistance to ciprofloxacin amongst Pseudomonas aeruginosa andStaphyloc-occus aureus: clinical significance and therapeutic approaches. J. Antimicrob. Chemother. (1990) 26 (Suppl. F):S165–179.
   Google Scholar
• BARBHAIYA R11, KNUPP CA, PITTMAN KA. Effect of age and gender on pharmacokinetics of cefepime. Antimi-crob. Agents Chemother. (1992) 36:1181–1185.
   PubMedGoogle Scholar
• BARRETT .JF, KLAUBERT DH: Is the new streptogramin derivative the answer to MRSA? Curr. Opin. Invest. Drugs (1993) 2(3):245–247.
   Google Scholar
• BARRE'TT JF, BERNSTEIN JI, LONGWILL HM, NGUYEN VN,OHEMENG KA: Use of polymyxin B nonapeptide to facilitate penetration of quinolone and novel gyrase inhibitors across gram-negative cell walls and mem-branes. Annual Meeting of the American Society for Micro-biology. Atlanta, Georgia: American Society for Microbiology, (1993): A129.
   Google Scholar
• BARRETT MS, JONES RN, ERWIN ME, JOHNSON DM, BRIGGS BM: Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628. Diagn. Microbiol. Infect. Dis. (1991) 14:389–401.
   PubMed Web of Science ®Google Scholar
• BARRETT MS, JONES RN, ERWIN ME, KOONTZ FP: CI-960, sparfloxacin, WIN57273, and isepamicin activity against clinical isolates of Mycobacterium avium-in-tracellularae complex, M. chekmae, and M. fortuitum. Diagn, Micrabiol. Infect. Dis. (1992) 15:169–171.
   PubMed Web of Science ®Google Scholar
• BARR1ERE JC, PARIS JM: RP 59500 and related semisyn-thetic streptogramins. Drugs of the Future (1993), 18(9):833–845. A recent review on RP 59500 and pristinamycins.
   Google Scholar
• BARR1ERE JC, BOUANCHAUD D, HARRIS NV, PARIS JM, SMITH C: The design, synthesis and properties of RP 59500 and related semi-synthetic streptogramin antibi-otics. 30th International Conference On Antimicrobial Agents And Chemotherapy, Atlanta, (1990), Abstr. 768.
   Google Scholar
• BARR1ERE JC, BOUANCHAUD DH, PARIS JM, ROLIN O, HARRIS NV, SMITH C: Antimicrobial activity against Staphylococcus aureus of semi-synthetic injectable steptogramins: RP59500 and related compounds. J. An-timicrob. Chemother. (1992) 30(Suppl A):1–8.
   Google Scholar
• BARRY A, FUCHS PC: In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin. Antimicrob. Agents Chemother. (1991) 35:955–960.
   PubMed Web of Science ®Google Scholar
• BARRY AL, FUCHS PC: Antistaphylococcal activity of the fluoroquinolones CI-960, PD131628, sparfloxacin,ofloxacin and ciprofloxacin. Eur.J. Clin. Micro biol. Infect. Dis. (1991) 10:168–171.
   PubMed Web of Science ®Google Scholar
• BARRY AL, FUCHS PC, CITRON DM, ALLEN SD, WEXLER HM: Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD131628 and clinafloxacin. J. Antimicrob. Chemother. (1993) 31:893–900.
   PubMed Web of Science ®Google Scholar
• BARTIZAL K, ABRUZZO GK, SCHMATZ DM: Biological activity of the pneumocandins. In: Cutaneous Ant fungalAgents (1993). Rippon JW, Fromtling RA (Eds), Marcel Dek-ker, New York. A detailed account of the biological activity of the pneumocandin natural products. Comparisons between these and echinocandins B and C, tetrahydroechinocandins B and C, cilofungin and am-photericin B is made.
   Google Scholar
• BARTIZAL K, ABRUZZO G, TRAINOR C, KRUPA D, NOLL-STADT K, SCHMATZ D, SCHWARTZ R, HAMMOND M, BALKOVEC J, VANMIDDLESWORTH F: In vitro antifungal activities and in vivo efficacies of 1,3-13-D-glucan synthe-sis inhibitors L-671,329, L-646,991, tetrahydroechino-candin B, and L-687,781, a papulacandin. Antimicrob. Agents Chemother. (1992) 36:1648–1657.
   PubMed Web of Science ®Google Scholar
• Comparison of pneumocandin Ao, cilofungin and tetrahydroechino-candin B.
   Google Scholar
• BARTIZAL K, ABRUZZO GK, FLATIERY AM, GILL CJ, SMITH JG, LYNCH L, PACHOLOK C, SCOUT, KONG L, KROPP H: Anti-Candida in vivo efficacy of water soluble lipopep-tides L-705,589, 1,731,373 and L-733,560. Program and Abstracts of the 33rd Interscience Conference on Antimicro-bial Agents and Chemotherapy, New Orleans, Louisiana, 1993 Abstr. 353. L-733,560 sterilized kidneys at O.09 mg/kg ip, bid X4, in a mouse disseminated candidiasis model.
   Google Scholar
• BALTERNFEIND A: Comparative in vitro activities of the new quinolone, Bay y 3118, and ciprofioxacin, spar-floxacin, tosufloxacin, CI-960 and CI-990. J. Antimicrob. Chemother. (1993) 31:505–522.
   PubMed Web of Science ®Google Scholar
• BEAULIEU D, TANG J, ZECKNER DJ, PARR Jr TR: Correia- tion of cilofunginin vivo efficacy with its activity against Aspergillus fumigatus (1,3)-0-D-glucan synthase. FEMS Micro biol. Lett. (1993) 108:133–138.
   PubMed Web of Science ®Google Scholar
• BENZ F. KNUSEL F, NUESCH J, TREICHLER H, VOSER W, NYFELER R, KELLER-SCHIERLEIN W: Stoffwechselpro-dukte von mikroorganismen. Echinocandin B, ein neuartiges polypeptid-antibioticum aus Aspergillus nidulans var. echinulatus: isolierung und bausteine. Hely. Chim. Ada (1974) 57:2459–2477.
   Google Scholar
• The first account of the echinocandin class of lipopeptides.
   Google Scholar
• BERGAN T, DA FONSECA J: Efficacy of cefcanel on staphlococci. Chemotherapy (1991) 37:43–49.
   PubMed Web of Science ®Google Scholar
• BERGAN T, DA FONSECA J: Antibacterial activity of cefcaneL Chemotherapy (1993) 39:96–104.
   Google Scholar
• BERNARD EM, EDWARDS FF, ARMSTRONG D, KURTZ MB: Activity of three pneumocandins in an animal model of pulmonary aspergillosis. Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993 Abstr. 354. Study showed effectiveness of three pneumocandin derivatives, L-693,989, L-731,373 and L-733,560, in a rat model of pulmonary aspergillosis. L-733,560 was effective when dosed at 0.625 mg/kg bid X7.
   Google Scholar
• BERTHAUD N, MONTAY G, HUET Y, BOURGUES A, BUS- SSIERE JC, SAUTEDE M, SELINGUE M, DESNOTTES JF: RP 59500, in vivo bactericidal activity in a model of S. aureus mouse infection: influence of varying the dos-age and the number of treatments. 32nd International Conference On Antimicrobial Agents And Chemotherapy Anaheim, (1992), Abstr. 1315.
   Google Scholar
• BERTHAUD N, ROMBI C, HUET Y, BOURGUES A, BUSSIERE JC, SAUTEDE M, SELINGUE M, DESNO11k,S JF: RP 59500: In vivo bactericidal activity in Streptococcus pneumo-niae mouse septicemia. 33rd International Conference On Antimicrobial Agents And Chemotherapy New Orleans, (1993), Abstr. 1157.
   Google Scholar
• BLACK FIR, BRIER GL, WOLNY JD, DORRBECKER SH: Pharmacology and pharmacokinetics of cilofungin. Program and Abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, Houston, Texas, 1989 Abstr. 1357. An account of Phase I tolerance studies with cilofungin.
   Google Scholar
• BLUMBACH J, DURCKHEIMER W, EHLERS E, FLEISHMANN seK, KLESEL N, LIMBERT M eta/.: Cefodizitne, an aminothia-zolylcephalosporin V. Synthesis and structure-activity relationships in the cefodizime series. J. Antibiotics (1987) 40:29–42.
   Google Scholar
• BLUMBERG HM, RIMLAND D, CARROLL DJ, TERRY P, WACHSMUTH 1K: Rapid development of ciprofloxacin resistance in methicillin-sitsceptible and -resistant Staphylococcus aureus. J. Infect. Dis. (1991) 163:1279–1285.
   PubMed Web of Science ®Google Scholar
• BLYN LB, BRAATEN BA, LOW DA: Regulation of PAP punphase variation by a mechanism involving differential Dam methylation states. EMBOJournal (1990) 9(12):4045–4054.
   PubMed Web of Science ®Google Scholar
• BOECK LD, FUKUDA DS, ABBOTT BJ, DEBONO M: Deacy-lation of echinocandin B by Actinoplanes utabensis. J. Antibiot. (1989) 42:382,
   PubMed Web of Science ®Google Scholar
• BONINA L, CARBONE M, MASTROENI P, COSTA GB, MAS-TROENI P: Effects of rufloxacin in Salmonella ty-phimurium infection in mice. J. Chemother. (1992) 4:353–357.
   PubMed Web of Science ®Google Scholar
• BOUANCHAUD DH: In vitro and in vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500.J. Antimicirob. Chem other. (1992) 30(Suppl. A):95-99. A reference article on synergistic activity of streptogramin compo-nents
   Google Scholar
• BOUANCHAUD DH: unpublished data.
   Google Scholar
• BOUFFARD FA, ZAMBIAS RA, DROPINSKI JF, BALKO'VEC JM, HAMMOND ML, NOLLSTADT KI-1, MARRINAN J: Syn-thesis and antiftmgal activity of water-soluble pneumo-candin Bo derivatives: L-705589, 1,731373, and L–733560.
   Google Scholar
• Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993 Abstr. 350. Synthesis of pneumocandin analogues L-705,589, L-731,373 and L-733,560 was described. The C. albicans glucan synthase inhibition IC5os were 11, 10 and 1 nM, respectively.
   Google Scholar
• BOUFFARD FA, ZAMBIAS RA, DROPINSKI JF, BALKOVEC JM, HAMMOND ML, ABBRUZZO GK, BARTIZAL KF, MAR-RINAN JA, KURTZ MB, MCFADDEN DC, NOLLSTADT RN, POWLES MA, SCHMATZ DM: Synthesis and antifungal activity of novel cationic pneumocandin Bo derivatives. Med. Chem. (1994) 37:(in press). Paper summarizing in vitro and in vivo activity of pneumocandin Bo, L-705,589, L-731,373 and L-733,560.
   Google Scholar
• BRAZHLTIKOVA MG, KUDINOVA MK, POPATOVA P, FIL- SLIFOVA TM, BOROWSKI E, ZELINSKY P, GOLIC J: Structureof the antibiotic madumycin. Bioorg. Khim.(1976) 2:149–157.
   Google Scholar
• BRIGGS GOODING B, ERWIN ME, BARRETT MSJOHNSONDM, JONES RM: Antimicrobial activities of two investiga-tional fluoroquinolones (CI-960 and E4695) against over 100 Legionella sp. isolates. Antimicrob. Agents Chemother. (1992) 36:2049–2050.
   PubMed Web of Science ®Google Scholar
• BRISSON AM, BRYSKIER A, MILLERIOUX L, FOURTELLANJB: Pharrnacokinetics of cefotiam administered intrave-nously and intramuscularly to healthy volunteers. An-titnicrob. Agents Chentother. (1984) 26:513–518.
   PubMed Web of Science ®Google Scholar
• BRODGEN RN, HEEL RC, SPEIGHI"TM, AVERY GS: Ce-furoxitne: a review of its antibacterial activity, pharma-cological properties and therapeutic use. Drugs (1979) 17:233–266.
   PubMed Web of Science ®Google Scholar
• BRODGEN RN, CARMINE A, HEEL RC, MORLEY PA, SPEIGHT TM, AVERY GS: Cefoperazone: a review of its in vitro antimicrobial activity, pharmacological prop-erties and therapeutic efficacy. Drugs (1981) 22:423–460.
   PubMed Web of Science ®Google Scholar
• BROTZU G: Richerche su di un nuovo antibiotico. Lavori Dell Instituto D'Igiene di Cagliari (1948) p1–11.
   Google Scholar
• BRUMFITT W, HAMILTON-MIT.T.FR JMT, SHAH S: In vitro activity of RP 59500, a new semisynthetic strepto-gramin, against Gram-positive bacteria. J. Antimicrob. Chemother. (1992) 30(Suppl. A):29–38.
   Google Scholar
• BRYSKIER A, PROCYK T, LABRO MT: Cefodizime, a new 2-aminothiazoly1 cephalosporin: physicochemical properties, toxicology and structure-activity relation-ships. J. Antimicrob. Chemotber. (1990) 26 (Suppl C):1–8.
   Google Scholar
• BRYSKIER A, PROCYK T, 'TREMBLAY D, LENFANT B, FOUR-TILLAN JB: Pharmacokinetics of cefodizime adminis-tered as a single-dose (1.0 and 2.0 g) to healthy adult volunteers. J. Antimicrob. Chemother. (1990) 26 (Suppl. C):65–70.
   Google Scholar
• BRYSKIER A, CHANTOT JF: Cefpirome (HR 810) - unenouvelle céphalosporine a large spectre. Pathol. Biol. (1985) 33:447–481.
   Google Scholar
• BRYSKIER A. Cefsulodine, structure, propriétés physi-cochimiques, bactériologiques et pharmacocinétiques. Lyon Pharm (1983) 34:343–355.
   Google Scholar
• BRYSKIER A: Classification des ll-lactamines. Pathol. Biol.(1984) 32:658–667.
   PubMedGoogle Scholar
• BRYSKIER A: Classification des céphalosporines et rela-tion activité structures des méthoxy-imino-aminothia-zole céphalosporines. Lyon Pharm (1983) 34:99–110.
   Google Scholar
• BRYSKIER A: Une nouvelle amino-2-thiazole cépha-losporine: le céfotiam (SCE 963). Structure, propriétés physicochirniques, bactériologiques et pharmaco-cinétiques. Lyon Pharm (1983) 34:191–203.
   Google Scholar
• BUCOURT R, HEYMES R, LUTZ A, PÉNASSE L, PERRONNET J. Céphalosporines a chaines amino-2-thiazoly1-4-acéty-les. Tetrahedron (1978) 34:2233–2243.
   Google Scholar
• BUENNING MK, WOLD JS: Ethanol-moxalactam interac-tions in vivo. Rev. Infect. Dis. (1982) 4 (Suppl.) S–555–563.
   Google Scholar
• BURTON PS, CONRADI RA, HILGERS AR: Mechanisms of peptide and protein absorption. Transcellular mecha-nism of peptide and protein absorption: passive as-pects. Advanced Drug Deliv. Rev. (1991) 7:365–386.
   Google Scholar
• Good discussion of factors affecting passive transport of peptides across cellular barriers. Presents a study showing effect of N-methy-lation of peptide bonds on transport across epithelium.
   Google Scholar
• BUTLER T, ZECKNER D, BOYLAN C, RAAB P, THOMAS L, GORDEE R, LUBBEHUSEN P, COUNTER F, SCHMIDTKE J: LY295337 a novel depsipeptide antifungal antibiotic. III. Resistance development studies. Program and Ab-stracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, 1992, Abstr. 498. LY297337 did not induce resistance in C. albicans after twelve passages in the presence of sub-inhibitory concentrations of LY295337.
   Google Scholar
• CAMA LD, CHRISTENSEN BG: Total synthesis of ll-lactam antibiotics. VII - Total synthesis of (±)-1-oxacepha-lothin_ J. Am. Chem. Soc. (1974) 96:7582–7584.
   PubMed Web of Science ®Google Scholar
• CAMPBELL MM, JOHNSON G, ROSS B, TEMPLEY MP: 2-aza-cephem. Tetrahedron (1990) 46:3973–3980.
   Google Scholar
• CANTON E, PEMAN J, JIMINEZ MT, RAMON, MS, GOBER-NADO, M: In vitro activity of sparfloxacin compared with those of five other quinolones. Antimicrob. Agents Chemother. (1992) 36:558–565.
   PubMed Web of Science ®Google Scholar
• CARMINE AA, BRODGEN RN, HEEL RC, SPEIGHT TM, AVERY GS: Cefotaxime: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs (1983) 25:223–289.
   PubMed Web of Science ®Google Scholar
• CASEWELL MW, SEYED-AKHAVANI M, WADE J: In vitro activity of RP 59500 against vancomycin-resistant En-terococcus faecium also resistant to 512mg/1 of gen-tamycin. 33rd International Conference On Antimicrobial Agents And Chemotherapy New Orleans,( 1993), Abstr. 1058.
   Google Scholar
• CESANA M, BROCCALI G, IMBIMBO BP, CREMA A: Effect of single doses of rufloxacin on the disposition of theophylline and caffeine after single administration. Internl. J. Clin. Pharmacol. Ther. Toxicol. (1991) 29:133–138.
   PubMed Web of Science ®Google Scholar
• CHAMBERLAIN JW, CHEN S: A2315, New antibiotics pro-duced by Actinopianes pbilippinensis. 2. Structure of A 2315A. J. Antibiotics (1977) 30(3)197–201.
   Google Scholar
• CHAMBERS HF: Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus. J. Antimi-crob. Chemother. (1992) 30 (Suppl. A):117–122.
   Google Scholar
• CHANTOT JF, ASZODI J, BONNET A, COSTEROUSSE G, TEUTSCH G: RU 45978 and RU 46069: in vitro and in vivo antibacterial activty of two new broad spectrum No-cephems. 28th Intersci. Conf Antimicrob. Agent Chemother. Los Angeles 1988 Abstr. 436.
   Google Scholar
• CHANTOT JF, BRYSKIER A. Cefpirome (HR 810) - Evalu-ation impérimentale de l'activité antibiotique in vitro et in vivo d'une nouvelle amino-2-thi27ole méthoxy-imino céphalosporine. Pathol. Biol. (1985) 33:482–486.
   PubMedGoogle Scholar
• CHENG AFB, LING TKW, LAM AW, FUNG KSC, WISER: The antimicrobial activity and ll-lactamase stability of cefpi-rome, a new fourth-generation cephalosporin in com-parison with other agents. J. Antimicrob. Chemother. (1993) 31:699–709.
   PubMed Web of Science ®Google Scholar
• CHIN NX, NEU HC: Post-antibiotic effect of RP 59500 against gram-positive bacteria compared to other agents. 31st International Conference On Antimicrobial Agents And Chemotherapy, Chicago, (1991), Abstr. 899. A relevant article on post-antibiotic effect
   Google Scholar
• CHIN NX, HUANG HB, WU JF, NEU HC: In vitro activity of AM-1155, a new fluoroquinolone, compared to other quinolones. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, (1993), Abstr. 1007.
   Google Scholar
• CHIN NX, HUANG HB, NEU TIC: In vitro activity of DU-6859a, a new fluoroquinolone. 33rd Interscience Con-ference on Antimicrobial Agents and Chemotherapy, New Orleans, (1993), Abstr. 983.
   Google Scholar
• CHIN NX, GU JW, NEU HC: In vitro activity of cefcanel versus other oral eephalosporins. Eur. J. Clin. Microbiol. Infect. Dis. (1991) 10:676–682.
   PubMed Web of Science ®Google Scholar
• Good comparison of cephalosporins in vitro.
   Google Scholar
• CHIN NX, GU JW, FANG W, NEU HC: In vitro activity of cefquinome, a new cephalosporin, compared with other cephalosporin antibiotics. Diagn. Microbiol. Infect. Dis. (1992) 15:331–337.
   PubMed Web of Science ®Google Scholar
• CHRIST W, LEHNERT T, ULBRICH B: Specific toxicological effects of quinolones. Rev. Infect. Dis. (1988) 10 (Suppl. 1):S141–146,
   Google Scholar
• CHUANG SE, DANIELS DL, BLATTNER FR: Global regula-tion of gene expression in Escbericbia coll. J Bacteriol (1993) 175(7):2026–2036.
   PubMed Web of Science ®Google Scholar
• CLARK AM: The need for new antifungal drugs. In: New Approaches ForAntifungal Drugs(1992). Femandes, BP (Ed), Birkhauser, Boston.
   Google Scholar
• COCHEREAU-MASSIN I, et al.: Efficacy and ocular pene- tration of sparfloxacin in experimental streptococcal endophthalmitis. Antimicrob. Agents Chemother. (1993) 37:633–636.
   Google Scholar
• COCITO C, CHINALI G: Molecular mechanism of action of virginiamycin-like antibiotics (synergirnycins) on the protein synthesis in bacterial cell-free systems. I Antimicrob. Chemother. (1985) 16(Suppl. A):35-52. A molecular explanation of the synergistic action of virginiamycin antibiotics in vivo is given.
   Google Scholar
• COCITO C: Antibiotics of the virginiarnycin family, inhibitors which contain synergistic components. Mi-crobiological Reviews (1979) 43(2):145–198.
   PubMedGoogle Scholar
• The reference article on the properties of virginiamycin-like antibi-otics.
   Google Scholar
• COCITO C: Properties of virginiamycin-like antibiotics(synergitnycins), inhibitors containing synergisticcomponents In: Antibiotics, Corcoran JN, Hahn FE (Eds), Springer, Berlin, Heidelberg, New York (1983), Vol VI:296–332.
   Google Scholar
• An important contribution in reviewing the properties of the strep-togramins.
   Google Scholar
• COHEN MA, HUBAND MD, MAILLOUX GB, YODER SL, ROLAND GE, HEIFETZ CL: in vitro activity of sparfloxacin (CI-978, AT-4140, and PD131501) a quinolone with high activity against Gram-positive bacteria. Diagn. Microbiol. Infect. Dis. (1991) 14:403–415.
   PubMed Web of Science ®Google Scholar
• COHEN MA, HUBAND MD, MAILLOUX GB, YODER SL, ROLAND GE, DAMAGALA JM, HEIFETZ CL: In vitro an-tibacterial activities of PD131628, anew 1,8-naphthyrid-ine anti-infective agent. Antimicrob. Agents Chemother. (1991) 35:141–146.
   PubMed Web of Science ®Google Scholar
• COHEN ML: Epidemiology of drug resistance: Implica- ions for a post-antimicrobial era. Science (1992) 257:1050–1055.
   PubMed Web of Science ®Google Scholar
• Discusses the rapid emergence of antibiotic resistance and the concerns for effects on future therapy.
   Google Scholar
• COLLATZ E, LABIA R, GUTMANN L: Molecular evolution of ubiquitous beta-lactamases towards extended-spec-trum enzymes against newer beta-lactam antibiotics. Mol. Micro biol. (1990) 4:1615–1620.
   PubMed Web of Science ®Google Scholar
• Excellent reivew of the impact of13-lactamases on cell-wall inhibitors.
   Google Scholar
• COLLINS L, MALANOSK1G, WENNERSTEN C, ELIOPOULOS MG, FERRARO MJ, MOELLERING RC:In vitro activity of RP 59500 an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. 32nd International Conference On Antimicrobial Agents And Che-motherapy Anaheim, (1992), Abstr. 1311.
   Google Scholar
• COOPER B, ROBINSON A, FREEMAN C, QUINTILIANI II R, MAZENS-SLTLLIVAN M, NIGHTINGALE C, QUINTILIANI R: Antimicrobial susceptibility of vancomycin-resistant enterococcL 33rd International Conference On Antimicro-bial Agents And Chemotherapy New Orleans, (1993), Abstr. 1053.
   Google Scholar
• COOPER MA, ANDREWS JM, ASHBY JP, MATTHEWS RS, WISE R: In vitro activity of sparfloxacin, a new qui-nolone antimicrobial agent. J. Antimicrob. Chemother. (1990) 26:667–676.
   PubMed Web of Science ®Google Scholar
• COOPER MA, ANDREWS JM, WISE R: In vitro activity of PD131628, a new quinolone antimicrobial agent. J. Antimicrob. Chemother. (1992) 29:519–527.
   PubMed Web of Science ®Google Scholar
• COPLEY-MERRIMAN CR, RANSBURG NJ, CRANE LR, KERK-ERING TM, PAPPAS PG, POTTAGE JC, HYSLOP DL: Cilo-fungin treatment of Canditta esopbagitis: Preliminary Phase II results. Program and Abstracts of the 30th Inter-science Conference on Antimicrobial Agents and Chemother-apy, Atlanta, Georgia, 1990 Abstr. 581. Successful treatment of Candida esophagitis in preliminary Phase II studies.
   Google Scholar
• COPLEY-MERRIMAN CR, GALLIS H, GRAYBILL JR, DOEB- BELING BN, HYSLOP DL: Cilofungin treatment of dis-seminated cadidiasis: Preliminary Phase 11 results. Pro-gram and Abstracts of the 30th lnterscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, 1990 Abstr. 582. A dose of 500 mg tid was effective for treatment of disseminated candidiasis in Phase II studies with cilofungin.
   Google Scholar
• CORSI M, POJANI G, DAL FORNO G, PIETRA C, GAVIRAGHI G, TRIST D: Analysis of the CCICa receptor antagonismof virginiamycin in guinea-pig ileum longitudinal myenteric plexus. Br.J. Pharmacol. (1993) 108:1164–1168.
   PubMed Web of Science ®Google Scholar
• COUROUX P, SCHIEVEN BC, HUSSAIN Z: Pneumocystis carinii. ASM News (1993) 59:179–181.
   Google Scholar
• COURTTEU AL, DRUGEON HB, BRYSKIER A, CHUNG SS, REYNAUD AA. Activité comparée de la cefsulodine sur les Pseudomonas aeruginosa, les Actinobacter et les entérobactéries. Pathol. Biol. (1982) 30:432–439.
   Google Scholar
• CRAIG W, EBERT S: Pharmacodynamyc activities of RP 59500 in an animal Infection model. 33rd International Conference On Antimicrobial Agents And Chemotherapy, New Orleans, (1993), Abstr. 470.
   Google Scholar
• CRUMPLIN GC: Mechanisms of resistance to the 4-qui-• nolone antibacterial agents . Journal of Antimicrobial Che-motherapy (1990) 26(SF):131–144.
   Google Scholar
• CULLMANN W: The threat of resistance to the new oral cephalosporins. Chemotherapy (1992) 38:10–17.
   PubMed Web of Science ®Google Scholar
• CURRAN WV, ROSS AA. 70-[2-(2-aminothiazol-4-y1)-(Z)-2- methoxyiminoacetamido]-3[(1,2,3-thiadiazol-5-yfithio methyliceph-3-em-4-carboxylic acid. A new potent cephalosporin derivative. J. Antibiotics (1983) 36:179–180.
   Google Scholar
• CURRENT W, BOYLAN CJ, RAAB PA: Anti-Pneumocystis activity of LY303366 and other echinocandin B analogs. Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993 Abstr. 368. A 5 mg/kg oral dose of LY303366 gave 99.7% reduction of cysts from the lungs of infected rats in a model of PCP.
   Google Scholar
• Rns NAC, EISENSTADT RL, EAST SJ, CORNFORD RJ, WALKER LA, WHITE AJ: Iron-regulated outer membraneproteins of Escbericbia coli K-12 and mechanism of action of catechol-substituted cephalosporins. Antimi-crob. Agents Chemother. (1988) 32:1879–1886.
   PubMedGoogle Scholar
• CURTIS NCA, EISENSTADT RI, EAST SJ, CORNFED RJ, WALKER LA, WHITE AJ. Iron-regulated outer membrane proteins of Escbeticbia colt K-12 and mechanism of action of catechol-substituted cephalosporins. Antimi-crob. Agents Chemother. (1988) 32:1879–1886.
   PubMed Web of Science ®Google Scholar
• DABERNAT H, SEGUY, DELMAS C: In vitro activity of RP 59500, a semi-synthetic streptogramin, againstHaemo-pbilus influenzae. 33rd International Conference On Anti timicrobial Agents And Chemotherapy New Orleans, (1993), Abstr. 226.
   Google Scholar
• DEBBIA EA, PESCE A, CHIESA M, RICOTTA N, SCFIITO GC: Microbiologk profile of ceftibuten, a new oral cepha-losporin. J. Antibiot. (1992) 18:129–139.
   Google Scholar
• DEBONO M, ABBOTT BJ, TURNER JR, HOWARD LC, GOR-DEE RS, HUNT AS, BARNHART M, MOLLOY RM, VUILLARD ICE, FUKUDA D, BUTLER TF, ZECKNER DJ: Synthesis and evaluation of LY121019, a member of a series of semi-synthetic analogues of the antifungal lipopeptide echi-nocandin B. Ann. N.Y. Acad. Sci. (1988) 544:152–167.
   PubMedGoogle Scholar
• The full account and structure-activity studies of side chain analogues of echinocandin B by the Lilly group. The choice of cilofungin (LY121019) as a candidate for further study was discussed.
   Google Scholar
• DEBONO M, ABBOTT BJ, FUKUDA DS, BARNHART M, WILLARD ICE, MOLLOY RM, MICHEL KR, TURNER JR, BUTLER TF, HUNT AR: Synthesis of new analogs of echinocandin B by enzymatic deacylation and chemical reacylation of the echinocandin B peptide: synthesis of the antifungal agent cilofungin (LY121019). j Antibiot. (1989) 42:389–397.
   PubMed Web of Science ®Google Scholar
• Describes the synthesis and physicochemical properties of cilo-fungin.
   Google Scholar
• DEBONO M, TURNER WW, LAGRANDEUR L, BURKHARDT F, RODRIGUEZ M, ZWEIFEL M, NISSEN J, CLINGERMAN K,GORDEE R, ZECKNER D, BUTLER T, PARR T, TANG J: LY303366 - A new semi-synthetic lipopeptide antifungal agent related to echinocandin B. Synthetic and struc-ture-activity studies. Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Che-motherapy, New Orleans, Louisiana, 1993 Abstr. 359. Poster describing the semi-synthesis and SAR of a number of polyaromatic side chain echinocandin analogues.
   Google Scholar
• DEFOSSA E, DÜRCKHEIMER W, FISCHER G, JENDRALLA H, KLESEL N, WOLLMANN T: Cefdaloxime pentexil tosilate (111(916 K) - a diastereomerically pure novel oral cepha-losporinester: synthesis and antibacterial acitivity in vivo. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy Anaheim (1992) Abstr. 187.
   Google Scholar
• DENNING DW, STEVENS DA: Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergIllosis. Antimicrnb. Agents Chemother. (1991) 35:1329–1333.
   PubMed Web of Science ®Google Scholar
• Cilofungin prolonged survival in this A. fumigatus mouse model at 62.5 mg/kg/day (ip, bid for eleven days) comparable in efficacy to amphotericin B given at 3.3 mg/kg/day (six total doses over eleven days).
   Google Scholar
• DESNO1thS JF, DIALLO N: RP 59500: In vitro antistaPhY- lococcal bactericidal activity across platelet-fibrin ma-trices compared to that of vancomycin. 33rd Interna-tional Conference On Antimicrobial Agents And Chemotherapy New Orleans, (1993), Abstact 763.
   Google Scholar
• DESNOTTES JF, DIALLO N: Cellular uptake and intracel-lular bactericidal activity of RP 59500 in murine macro-phages. J. Antimicrob. Chemother. (1992) 30(Suppl. A):107–115.
   Google Scholar
• DI GAMBATTISTA M, ENGELBORGHS Y, NYSSEN E, CO- CITO C: Kinetics of binding of macrolides, lin-cosamides, and synergimycins to ribosomes. J. Biol. Chem. (1987) 262:8591–8597.
   PubMed Web of Science ®Google Scholar
• DI GAMBATTISTA M, CHINALI G, COCITO C: The molecu-lar basis of the inhibitory activities of the type A and type B synergimycins and related antibiotics on ribo-somes. J. Antimicrob. Chemother. (1989) 24:485–507.
   PubMed Web of Science ®Google Scholar
• DI GAMBATTISTA M, ENGELBORGHS Y, NYSSEN E, CLAYS K, COCITO C: Interaction between virginiamycin S and ribosomes is partly provided by a salt bridge with a Mg2+ Biochemistry (1991) 30:7277-7282. A relevant article on the biological importance of the 3-hydroxy picolinic acid residue in group B streptogramins.
   Google Scholar
• DI GAMBATTISTA M, NYSSEN E, PECHER A, COCITO C: Affinity labelling of the virginiamycin S binding site onbacterial ribosome. Biochemistry (1990) 29:9203–9211.
   PubMedGoogle Scholar
• An advance in the mechanism of action of streptogramins.
   Google Scholar
• DI GAMBATTISTA M, SHARMA NK, ANTEUNIS MJO: Some simple conjugates of virginiamycin and their bio-activ-ity. Bull. Soc. Chim. Beiges (1990) 99:195–211.
   Google Scholar
• DOEBBELING BN, FINE BD, PFALLER MA, SHEETZ CT, STOKES TB, WENZEL RP: Acute tubular necrosis (ATN) and anion-gap acidosis during therapy with cilofungin (LY-121019) in polyethylene glycol (PEG). Program and Abstracts of the 30th Interscience Conference on Antimicro-bial Agents and Chemotherapy, Atlanta, Georgia, 1990 Abstr. 583. Toxicity due to PEG-300 cosolvent used in cilofungin formulation.
   Google Scholar
• DOOR MB, WEBB CL, BRON N, JASSOS AB: Single-dose tolerance and pharmacokinetics of CI-960 (P1)127391) In healthy volunteers. 31st Interscience Conference of Antimicrobial Agents and Chemotherapy, Chicago, (1991), Abstr. 1154.
   Google Scholar
• DUBOIS J, JOLY JR: In vitro activity of RP 59500, a new synergistic antibacterial agent, against Legionella spp. Antimicrob. Chemother. (1992) 30(Suppl. A):77–82.
   Google Scholar
• DeRCICHEIMER W, BLUMBACH J, LATRELL R, SCHEUNE-MANN RH Recent development in the field of O-1actam antibiotics. Ang Chem (1985) 24:180–202.
   Google Scholar
• EJIMA A, HAYANO T, EBATA T, NAGAHARA T, KODA H, TAGAWA H, FURUKAWA M. Synthesis and antimicrobial activity of cephalosporins with a 1-pyridinium substi-tuent carrying a 5-membered heterocycle at the C-3 position. J. Antibiotics (1987) 40:43–48.
   Google Scholar
• EL SOLH N, LONCLE V, AUBERT S, CASETTA A, ALLIGNET J: Analysis of Staphylococcal elements conferring resis-tance to streptogramin A (RP 54476). 33rd International Conference On Antimicrobial Agents And Chemotherapy New Orleans, (1993), Abstr. 217.
   Google Scholar
• ELIOPOULOS GM, KLIMM K, ELIOPOULOS CT, FERRARA MJ, MOELLERING RC:In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-posi-tive bacteria. Antimicrob. Agents Chemother. (1993) 37:366–370.
   PubMed Web of Science ®Google Scholar
• ENG RHK, CHERUBIN C, SMITH SM, BUCCINI F: Inoculum effect of 13-lactam antibiotics on Enterobacteriaceae. Antimicrob. Agent Chemother. (1985) 28:601–606.
   PubMed Web of Science ®Google Scholar
• ENGLISH AR, RETSEMA JA, GIRARD AE, LYNCH JE, BARTH WE: CP-45,899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactatns: initial bac-teriological characterization. Antimicrobial Agents and Chemotherapy (1978) 14:414–419.
   PubMed Web of Science ®Google Scholar
• ETIENNE SD, MONTAY G, LE LIBOUX A, FRYDMAN A, GARAUD JJ: A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500. J. Antimicrob. Chemother. (1992) 30(Suppl. A):123–131.
   Google Scholar
• The first study published on tolerance and pharmacokinetics of RP 59500 in man.
   Google Scholar
• EVANS DA, WEBER AE: Synthesis of the cyclic hexapep- tide echinocandin D. New approaches to the asymmet-ric synthesis of 13-hydroxy a-amino acids. J. Am. Chem. Soc. (1987) 109:7151–7157.
   Google Scholar
• Second synthesis of echinocandin D.
   Google Scholar
• FANTIN B., VALLOIS DM., OTTAVIANI M, MAZIERE B, GARRY L, POCIDALO JJ, CARBON C: Autoradiographic Pattern of diffusion of "C RP 59500 throughout infected cardiac vegetation in rabbits. 33rd International Confer-ence On Antimicrobial Agents And Chemotherapy New Or-leans, (1993), Abstr. 161.
   Google Scholar
• FAOAGALI JL, THONG ML, GRANT D: Ten years' experi-ence with methiciRin-resistant Staphylococcus aureus In a large Australian hospital Journal ofHospital Infection (1992) 20:113–119.
   Google Scholar
• FELMINGHAM D, ROBBINS MJ, GHOSH G, et al.: In vitro studies with DU-6859a, a new fluoroquinolone antimi-crobiaL 33rd Interscience Conference on Antimicrobial Agents Chemotherapy, New Orleans, (1993), Abstr. 981.
   Google Scholar
• FILLASTRE JP, LEROY A, GODIN M, OKSENHENDLER G, HUMBERT G: Pharmacokinetics of cefoxitin sodium in normal subjects and ureamic patients. J. Antimicrob. Chemother. (1978) 4 (Suppl B):79–83.
   Google Scholar
• FIRESTONES RA, FAHEY JL, MACIEJEWICZ NS, PATEL GS, CHRISTENSEN BG: Total synthesis of (±)-1-carbacefoxi-tin and cefamandole and (±)-1-oxacefamandole. J. Med. Chem. (1977) 20:551–556.
   PubMedGoogle Scholar
• FONT DE MORA J, HERRERO E, SENTANDREU R: A kinetic study on the regeneration of Candida albicans proto-plasts in the presence of cell wall synthesis inhibitors. FEMS Microbiot Lett. (1993) 108:43–48.
   PubMedGoogle Scholar
• Study shows that glucans are still formed in the presence of 13-(1,3)-glucan synthesis inhibitors, but the glucan is no longer cell wall bound. FOORD RD: Cefuroxime: human pharmacokinetics. An-timicrob. Agents Chemother. (1976) 9:741–750.
   Google Scholar
• FORD AS, BALTCH AL, SMITH RP, RITZ W: In vitro suscep-tibilities of Pseudomonas aeruginosa and Pseudo-monas spp. to the new fluoroquinolones clinafloxacin and P13131628 and nine other antimicrobial agents. J. Antimicrob. Chemother. (1993) 31:523–532.
   Google Scholar
• FORSTALL GJ, KNAPP CC, WASHINGTON JA: Activity of new quinolones against ciprofloxacin-resistant staphy-lococci. Antimicrob. Agents Chemother. (1991) 35:1679–1681.
   PubMed Web of Science ®Google Scholar
• FOURTILLAN JB, LEROY A, LEFEBVRE MA, HUMBERT G, FILLASTRE JP, REUMONT G, RAMIS N: Cross-over study of pharmacokinetics of cefonicid administered intrave-nously or intramuscularly to healthy adult humans. Eur. J. Drug Metab. Pharrnacok. (1985) 10:225–230.
   PubMed Web of Science ®Google Scholar
• FOURTILLANp, BRISSON AM, BECQ-GIRAUDON B: Etude pharmacocinétique de la cefopérazone (T-1551) chez l'honune, aprés administration intraveineuse de doses de 1 gramme et 2 grammes. Dosages effectués par chromatographie liquide haute performance. Med. Mal. Infect. (1982) 12 (Suppl):21–26.
   Google Scholar
• FOURTILLAN JB, BRYSKIER A, MIGNOT A, BORSA F, HUM-BERT G: Pharmacokinetic study of cefmenoxime (SCE-1365-CMX) in healthy adults. Am . J. Med. (1984) 77 (Suppl. 6A):28–31.
   Google Scholar
• FOURTILLAN JB, BRISSON AM: Pharmacocinétique com-parée du moxalactam et d'autres céphalosporines. Se-maines des Hopitaux de Paris (1983) 59:1968–1971.
   PubMedGoogle Scholar
• FOX R, NEAL KR, LEEN CLS, ELLIS ME, MANDAL BK: Fluconazole resistant Candida in AIDS. J. Infect. (1991) 22:201–204.
   PubMed Web of Science ®Google Scholar
• FRANKMOLLE WP, LARSEN LK, CAPLAN FR, PATTERSON GML, KNUBEL G, LEVINE IA, MOORE RE: Antifungal cyclic peptides from the terrestrial blue-green algaAnabaena-taxa .1. Isolation and biological properties. J. Antibiot. (1992) 45:1451–1457.
   Google Scholar
• FRANKMOLLE WP, KNUBEL G, MOORE RE, PAI1ERSONGML: Antifungal cyclic peptides from the terrestrial blue-green alga Anabaena-laxa .2. Structures of laxaphycins A, B, D and E. J. Antibiot. (1992) 45:1458–1466.
   Google Scholar
• FRANZBLAU SG, PARRILLA MLR, CHAN GP: Sparfloxacin is more bactericidal than ofloxacin against Mycobac-terium leprae in mice. Intl. J. Lepro. (1993) 61:66–69.
   Google Scholar
• FREMALTX A, SISSIA G, COHEN R, GESLIN P: In vitro activity of RP 59500, a new semisynthetic strepto-gramin, against Streptococcus pneumoniae. J. Antimi-crob. Chemother. (1992) 30 (Suppl. A):19–24.
   Google Scholar
• FREMAUX A, SISSIA G, ROSEMBAUM M, GESLIN P: In vitro activity of cefpirome (HR 810), anew parenteral cepha-losporin against penicillin susceptible and resistant pneumococci 32nd Intersci. Conf. Antimicrob. Agent Chemother. Anaheim 1992. Abstr. 1020.
   Google Scholar
• FROMTLING RA, ABRUZZO GK: L-671,329, a new antifun- gal agent. M. In vitro activity, toxicity, and efficacy in comparison to aculeacin. J. Antibiot. (1989) 42:174-178. A direct comparison in vitro and in vivo of pneumocandin Ao (L:671,329) and aculeacin. The compounds possess similar poten-cies.
   Google Scholar
• FROST DJ, DRAKE RR, WASSERMAN BP: (1,3)-13-Glucan synthase from Saccharomyces cerevisiae . In vitro acti-vation by O-lactoglobulin or Brij-35, and photoaffinhy labeling of enriched microsomal fractions with 5-azido-UDP-Glc and 8-azido-GTP. Curr. Microbiol. (1992) 24:295–300.
   Google Scholar
• FU KP, LAFREDO SC, FOLENO B, ISAACSON DM, BARRETT JF, TOBIA AJ, ROSENTHALE, ME: In vitro and in vivoantibacterial activities of levofloxacin (1-ofloxacin), an optically active ofloxacin. Antimicrob. Agents Chemother. (1992) 36:860–866.
   PubMed Web of Science ®Google Scholar
• FU K.P, FOLENO BD, LAFREDO SC, LOCOCO JM, ISAACSON DM:In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin. An-timicrob. Agents Chemother. (1993) 37:301–307.
   PubMed Web of Science ®Google Scholar
• FUCHS PC, BARRY AL, PFALLER MA, ALLEN SD, GERLACH EH: Multicenter evaluation of the in vitro and in vivo activities of three new quinolones, sparfloxacin, CI-960 and PD131628, compared with the activity of ciproflox-acin against 5,252 clinkal bacterial isolates. Antimicrob. Agents Chemother. (1991) 35:764–766.
   PubMed Web of Science ®Google Scholar
• FUJIE R, YOSHIOKA H, OKUNO A, FUJITA K, MURONO K, SAKATA SMH, ISEKI K, WAGATSUMA Y et al.: Pharnaacok-inetic and clinical studies of cefditoren pivoxil in the pediatric field. Jpn. J. Antibiot. (1993) 46:95–114.
   PubMedGoogle Scholar
• FUJII R, NISHIMURA T, SUNAKAWA K: Cefditoren pivoxil (CDTR-PI): pharmacokinetics. Influence on carnitine metabolism and clinical evaluation in pediatric pa-tients. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 897.
   Google Scholar
• FUJII R, SUNAKAWA K, YAMAMOTO S: Carnitine status of S-1108 in pediatric patients with various infectious diseases. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy Anaheim (1992) Abstr. 186.
   Google Scholar
• FUKASAWA M, NOGUCHI H, OKUDA T et al.: In vitro antibacterial activity of SM-1652, a new broad spectrum cephalosporin with antipseudomonal activity. Antimi-crob. Agents Chemother. (1983) 23:195–200.
   PubMed Web of Science ®Google Scholar
• FUKUOKA Y, IKEDA Y, YAMASHIRO Y, TAKAHATA M, TODO Y, NARITA H: In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimi-crob. Agents Chemother. (1993) 37:384–392.
   PubMed Web of Science ®Google Scholar
• GALLIS HA, DREW RH, PICKARD WW: Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. (1990) 12:308–329.
   PubMedGoogle Scholar
• GARCIA I, PASCUAL A, GUZMAN MC, PEREA EJ: Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells. Antimicrob. Agents Chemother. (1992) 36:1053–1056.
   PubMed Web of Science ®Google Scholar
• GEM F RT M, MIZUUCHI K, O'DEA MH, ITOH T, TOMIZAWA J: Nalidixic acid resistance: a second genetic charac-teristic involved in DNA gyrase activity. Proceedings of the National Academy of Science, USA (1977) 74:4772–4776.
   PubMed Web of Science ®Google Scholar
• GEORGOPAPADAKOU NH, ALBRECHT HA, BERTASSO A, MCCAFFREY C: Mode of action of Ro 25–0534, a 3'-tertiary amine-linked dual action cephalosporin. 33rd Inter-science Conference on Antimicrobial Agents and Chemother-apy New Orleans (1993) Abstr. 1493.
   Google Scholar
• GEORGOPOULOS A, BREYER S, FEISTANER S, STAUFFER F, MARKRISTATH1S A, GEORGOPOULOS M., GRANINGER W: Bactericidal effect of RP 59500 against staphylococci with different phenotypes in a diffusion chamber model in rabbits. 32nd International Conference On An-timicrobial Agents And Chemotherapy Anaheim, (1992), Abstr. 1309.
   Google Scholar
• GIBBONS A: Exploring new strategies to fight drug-re-sistant microbes. Science (1992) 257:1036–1038.
   PubMed Web of Science ®Google Scholar
• Gives an editorial overview of the implications of antibiotic resis-tance.
   Google Scholar
• GILFILLAN EC, PELAK AB, FROMTLING RA, BLAND J, HADLEY S, GADEBUSH HH: L-656575 (0PC-9-176): a novel oxacephem. Pharmacokinetics and experimental Chemotherapy. J. Antibiotics (1988) 41:1137–1141.
   PubMedGoogle Scholar
• GIRARD AE, FAIELLA JA, CIMOCHOWSKI CR, BRIGHTY KE: In vivo activity of CP-99,219 in models of acute and localized infection in mice. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, (1993), Abstr. 1510.
   Google Scholar
• GLADUE RP, BRIGHT GM, ISAACSON RE, NEWBORG MF: In vitro and in vivo uptake of azhhromycin (CP-62,993) by phagocytic cells: possible mertmoism of delivery and release at sites of infection. Antimicrobial Agents and Chemotherapy (1989) 33:277–282.
   PubMed Web of Science ®Google Scholar
• Describes a novel method of drug delivery to sites of infections.
   Google Scholar
• GOHARA Y, et al.: In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumo-niae. Antimicrob. Agents Chemother. (1993) 37:1826–1830.
   Google Scholar
• GOLDSTEIN EJ: Patterns of susceptibility to fluoroqui-nolones among anaerobic bacterial isolates in the United States. Clin. Infect. Dis. (1993) 16 (Suppl. 4):S377–S381.
   Google Scholar
• GOLDSTEIN EJC, CITRON DM: Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bac- teria. Antimicrob. Agents Chemother. (1992) 36:1158-1162. A thorough data summary describing the in vitro activity of several quinolones against clinically important anaerobes.
   Google Scholar
• GOLLAPUDI SV, CHUAH SK, HARVEY T, THADEPALLI FID, TFIADEPALLI H: In vivo effects of rufloxacin and ciprofloxacin on T-cell subsets and tumor necrosis factor production in mice infected with I3acteroides fragilis. Antimicrob. Agents Chemother. (1993) 37:1711–1712.
   PubMed Web of Science ®Google Scholar
• GOODING BB, JONES RN:In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. An-timicrob. Agents Chemother. (1993) 37:349–353.
   PubMed Web of Science ®Google Scholar
• GOOTZ TD, BRIGHTY ICE, ANDERSON ME, HASKELL SL, SUTCLIFFE JA, CASTALDI MJ, MILLPR SA: In vitro activity and synthesis of CP-99,219, a novel 7-(3-azabicy-clo[3.1.0] hexyDnaphthyridone. 32nd Interscience Con-ference on Antimicrobial Agents and Chemotherapy, Ana-heim, (1992), Abstr. 751.
   Google Scholar
• GORDEE R, FARMER J, FLOKOWITSCH J, HAEBER P: In vitro antifungal activity of LY303366, a new antifungal agent derived from echinocandin B. Program and Ab-stracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993Ab-stract 360. Poster presenting the activity of LY303208, LY303366 and LY307863 against Candida, Aspergillus, Blastomyces, Histoplasma and Crypto-coccus. Kill curves demonstrate the fungicidal nature of LY303366.
   Google Scholar
• GORDEE R, FARMER J, ZECKNER D: LT295337 a novel cyclic depsipeptide antifungal antibiotic. L In vitroantifungal activity. Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Che-motherapy, Anaheim, California, 1992, Abstr. 496.
   Google Scholar
• GORDEE RS, ZECKNER DJ, ELLIS LF, THAKKAR AL, HOWARD LC: In vitro and in vivo anti-Candida activity and toxicology of LY121019. J. Antibiot. (1984) 37:1054–1065.
   PubMed Web of Science ®Google Scholar
• Contains a full description of activity, and toxicology results with cilofungin and several side chain analogues.
   Google Scholar
• GORDEE RS, ZECKNER DJ, HOWARD LC, AIBORN WE, DEBONO M: Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptkle antifun- gal antibiotic. Ann. N.Y. Acad. Sci. (1988) 544:294–301.
   PubMedGoogle Scholar
• The activity and toxicity of cilofungin is presented.
   Google Scholar
• GOTO S, AOKI K, MIYAZAKI S, TSUJI A: In vitro and in vivo antibacterial activities of AM-1155, a new qui-nolone. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, (1992), Abstr. 1002.
   Google Scholar
• GOTO S, TAICAHISHI H, MIYAZAKI S, KANEKO Y, YAMA-GUCHI K: In vitro and in vivo antibacterial activities of T-3761, anew fluoroquinolone. 33rd Interscience Confer-ence on Antimicrobial Agents and Chemotherapy, New Or-leans, (1993), Abstr. 1012.
   Google Scholar
• GRAYBILL JR: Future directions of antifungal chemo-therapy. Clin. Infect. Dis. (1992) 14 (Suppl. 1): S170–181.
   Google Scholar
• GRONEBERG RN: Changes in the antibiotic sensitivities of urinary pathogens 1971-1989. J. Antimicrob. Chemother. (1990) 26:3–11.
   PubMed Web of Science ®Google Scholar
• GU J-W, FANG W, NEU HC: Plasma bactericidal activity of a new C-5 methyl fluoroquinolone after oral dosesof 400 and 800 mg. J. Clin. Pharmacol. (1992) 32:804–807.
   PubMed Web of Science ®Google Scholar
• GU JW, CHIN pc, NEU HC: In vitro activity of an oxy- cephem OPC 9–176 compared with its sulfur analogue 197 and other 13-lactams. Diagn. Micro biol. Infect. Dis. (1991) 14:135–140.
   Google Scholar
• HAJDU R, THOMPSON R, WHITE K, STARK MURPHY B, KROPP H: Comparative pharmacolcinetics of three water-soluble analogues of the lipopetide antifungal compound L-688,786 in mice and rhesus monkeys. Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993 Abstr. 357. L-733,560 showed superior rhesus pharmacokinetics compared to L-688,786, L-705,589 and L-731,373. IV dosing at 5 mg/kg gave plasma levels of 5 j.tg/mL for 24 hours.
   Google Scholar
• HAKIMELAHI GH, KHALAFI-NEZHAD A: The synthesis of (611*, 7R*)-4-carboxy-3-hydroxy-7-phenylacetamido-2-isooxacephem. Hely Chem Acta (1984) 67:18–20
   Google Scholar
• HAMMOND ML: Chemical and structure-activity studies of the echinocandin lipopeptides. In: Cutaneous Antifun-gal Agents (1993). Rippon JW, Fromtling RA (Eds), Marcel Dekker, New York. A detailed account of the discovery and isolation of the echino-candin, aculeacin, sporiofungin, mulundocandin and pneumocandin natural products with emphasis on chemical and structure-activity aspects.
   Google Scholar
• HARA K, KOHNO S, KOGA H, SAITO A, OHMICHI M, HIRAGA Y, TAKEBE K, YOSHIDA T, ITO T, WATANABE Ket al.: A comparative study of cefclidin and ceftazidime In chronic respiratory tract infections. Chemotherapy (Tokyo) (1993) 41:104–127.
   Google Scholar
• HARA K, KOHNO S, KOGA H, OE T, KATSUMATA T, ASAI S, MASHIMOTO H, SUYAMA T, WATANABE K, IRIFUNE K etal.: A comparative study of cefclidin and ceftazidime In bacterial pneumonia. Chemotherapy (Tokyo) (1993) 41:78–103.
   Google Scholar
• HARA K, KOHNO S, YAMAGUCHI K, SHIMADA J: Cefpimi-zole sodium- a new cephalosporin. Drugs Today (1987) 23:321–327.
   Google Scholar
• HARRIS AM. Catechol-substituted cephalosporins. Cum Opin. Invest. Drugs (1993) 2:109–118.
   Google Scholar
• HARTMANN B, TOMASZ A: Altered penicillin-binding proteins in methicillin-resistant strains ofStaphylococ-cus aureus. Antimicrob. Agents Chemother. (1981) 19:726–735.
   PubMed Web of Science ®Google Scholar
• Healthcare Forecasting: Increased sales of fluorinated quinolones. (1992) Issue 32.
   Google Scholar
• HENSENS OD, LIESCH JM, ZINK DL, SMITH JL, WICHMANN CF, SCHWARTZ RE: Pneumocandins from Zaterion ar-boricola III. Structure elucidation. J. Antibiot. (1992) 45:1875–1885.
   PubMed Web of Science ®Google Scholar
• HIRUMA R, UENO J, MORIYAMA M, NEGI S, KATSU K: E1101, a new oral cephalosporin: II. In vitro antibacte-rial activity. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 895.
   Google Scholar
• HIRUMA R, MORIYAMA M, UENO J, TOYOSAWA T, HATA K, UEMURA Y, KATSU K: E1101, a new oral cepha-losporin: Bl. In vivo antibacterial activity. 33rd Inter-science Conference on Antimicrobial Agents and Chemother-apy New Orleans (1993) Abstr. 896.
   Google Scholar
• HITCHCOCK CA, PYE GW, TROKE PF, JOHNSON EM, WARNOCK DW: Fluconazole resistance in Candida-glabrata. Antimicrob. Agents Chemother. (1993) 37:1962–1965.
   PubMed Web of Science ®Google Scholar
• HOBAN DJ, WESNOWESKI B, PALATNICK L, ZHANEL CJ, DAVIDSON RJ: In vitro activity of streptogramin RP 59500 against staphylococci, including bactericidal ki-netic studies. J. Antimicrob. Chemother. (1992) 30(Suppl. A):59–66.
   Google Scholar
• HOFFLER D, RO I IER-TUMPACH W, KOEPPE P, WIESE K. Pharmacokinetics of SCE-2787, a new cephalosporin for intravenous administration, in healthy subjects and patients with renal failure. Acta Therapeuttca (1992) 18:117–132.
   Google Scholar
• HOLTJE JU, TOMASZ A: Purification of the pneumococcal N-acetylmuramy1-1-alanine amidase to biochemical ho-mogeneity. Journal of Biological Chemistry (1976) 251:4199–4207.
   PubMed Web of Science ®Google Scholar
• HOOPER DC, WOLFSON JS: Mechanisms of bacterial resistance to quinolones. In: Quinolone Antimicrobial Agents, 2nd Edition (1993) Hooper, DC., Wolfson, JS (Eds) American Society for Microbiology, Washington, DC.
   Google Scholar
• HOOPER DC, WOLFSON JS: Adverse effects of qui- nolones. In: Quinolone Antimicrobial Agents, 2nd Edition(1993) Hooper DC, Wolfson JS (Eds), American Society for Microbiology, Washington, DC. A thorough review of adverse effects seen with ciprofloxacin, norfloxacin and ofloiracin.
   Google Scholar
• HOOPER DC, WOLFSON JS: Bacterial resistance to the quinolone antimicrobial agents. Amer. J. Med. (1989) 87 (Suppl. 6C):17S–235.
   Google Scholar
• HOSAKA M, YASUE T, FUKUDA H, TOMIZAWA H, AOYAMA H, HIRAI H: In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy qui-nolone. Antimicrob. Agents Chemother. (1992) 36:2108–2117.
   PubMed Web of Science ®Google Scholar
• HRMOVA M, TAFT CS, SELITRENNIKOFF CP: 1,3-13-Glucan synthase of Neurospora-crassa: Partial purification and characterization of solubilized enzyme activity. Ever. Mycol. (1989) 13:129–139.
   Google Scholar
• HUBAND MD, COHEN MA, MESERVEY MA, ROLAND GE, YODER SL, DAZER ME, DOMAGALA JM: In vitro antibac-terial activities of PD138312 and PD140248, new fluoro-naphthyridines with outstanding Gram-positive po-tency. Antimicrob. Agents Chemother. (1993) 37:2563–2570.
   PubMed Web of Science ®Google Scholar
• HUSSON MO, IZARD D, BRYSKIER A, LECLERC H. Anti-pseudomonal activity of HR 810. Infection (1985) 13:85–86.
   PubMed Web of Science ®Google Scholar
• IIMURA S, IMAE K, HASEGAWA T, OKITA T, TAMAOKA M, MURATA 5, KAMACHI H, KAMEI H. Cephalosporins hav-ing a heterocyclic catechol in the C3 side chain IL Improvement of pharmacokinetic profile. J. Antibiotics (1993) 46:850–857.
   Google Scholar
• IIZAWA Y, OKONOGI K, HAYASHI R, IWAHI T, YAMAZAKI T, IMADA A: Therapeutic effect of cefozopran (SCE-2787), a new parenteral cephalosporin, against experi-mental infections in mice. Antimicrob. Agents Chemother. (1993) 37:100–105.
   PubMed Web of Science ®Google Scholar
• IKAI K, TAKESAKO K, SHIOMI K, MORIGUCHI M, UMEDA Y, YAMAMOTO J, KATO I, NAGANAWA H: Structure of aureobasidin-A. j Antibiot. (1991) 44:925–933.
   PubMed Web of Science ®Google Scholar
• IKAI K, SHIOMI K, TAKESAKO K, MIZUTANI S, YAMAMOTO J, OGAWA Y, UENO M, ICATO I: Structures of aureobasid-ins B to R. J. Antibiot. (1991) 44:1187–1198.
   PubMedGoogle Scholar
• IMADA T, MIYAZAKI S, NISHIDA M, YAMAGUCHI K, GOTO S: In vitro and in vivo antibacterial activities of a new
   Google Scholar
• IMAE K, IIMURA S, HASEGAWA T, OKITA T, HIRANO M, KAMACHI H, KAMEI H. Cephalosporins having a hetero-cyclic catechol in the C3 side chain L Enhancement of efficacy against Gram-negative bacteria. J. Antibiotics (1993) 46:840–849.
   Google Scholar
• IMBIMBO BP, BROCCALI G, CESANA M, CREMA F, AT-TARDO-PARRINELLO G: Inter- and intrasubject variabili-ties in the pharmacolcinetics of rufloxacin after single oral administration to healthy volunteers. Antimicrob. Agents Chemother. (1991) 35:390-393. A useful study that highlights the extreme variability in pharrnacok-inetic properties seen between subjects given rufloxacin.
   Google Scholar
• INAMOTO Y, CHIBA T, KAMIMURA T, TOKAYA T: FK 482, a new orally active cephalosporin: synthesis and bio-logical properties. J. Antibiotics (1988) 41:828–830.
   PubMed Web of Science ®Google Scholar
• INAMOTO Y, GOTO J, SAKANE K, KAMIMURA T, TAKAYA T: Studies on O-LIctam antibiotics XIX. Structure-activity relationships of cephalosporins having a thiadia-zolylthiomethyl group at the C-3 side chain. J. Antibiot. (1991) 44:507–516.
   Google Scholar
• INOKOSHI J, TAKESHIMA H, IKEDA H, OMURA S: Cloning and sequencing of the aculeacin-A acylase-encoding gene from Acinoplanes utabensis and expression in Streptomyces lividans. Gene (1992) 119:29–35.
   PubMed Web of Science ®Google Scholar
• Aculeacin A acylase is apparently the same enzyme described by Lilly for the deacylation of echinocandin B.
   Google Scholar
• INOKOSHI J, TAKESHIMA H, IKEDA H, OMURA S: Efficient production of acuJeadit A acylase in recombinant Streptomyces strains. Appl. Microbiol. Biotechnol. (1993) 39:532–536.
   Web of Science ®Google Scholar
• INOUE E, MITUSHASHI S: Interactions of E-1040 with cephalosporinase from Citrobacter freundii. Antimi-crob. Agents Chemother. (1990) 33:2157–2159.
   Web of Science ®Google Scholar
• INOUE M, TAMURA A, YOSHIDA T, OKAMOTO R, ATSUMI K, NISHIHATA K, MITUHASHI S: A novel cephalosporin, ME-1207 - in vitro and in vivo activities. 25th Interscience Conference on Antimicrobial Agents and Chemotherapy Min-neapolis (1985) Abstr. 582.
   Google Scholar
• ISAACS RP, KUNKE PJ, COHEN RL, SMITH, J'W: Ciproflox-acin resistance in epidemic methicillin-resistant Staphylococcus aureus. lancet (1988) II: 843.
   Google Scholar
• ISAACSON RE. Pilus adhesins. In: Bacterial Adhesion (1985). Savage DC, Fletcher M, (Eds.), Plenum PublishingCorporation, New York: pp. 307–336.
   Google Scholar
• ISERT D, FISCHER G, ICLESEL N, LIMBERT M, MARKUS A, RIESS G, SEIBERT G: Cefdaloxitne pentexil tosilate (HR916 K): a diastereomerically pure novel oral cepha-losporinester with outstanding absorption charac-teristics. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy Anaheim (1992) Abstr. 188.
   Google Scholar
• ITO T, OTSUKI M, NISHINO T: In vitro antibacterial activity of Q-35, a new fluoroquinolone. Antimicrob. Agents Chemother. (1992) 36:1708–1714.
   PubMed Web of Science ®Google Scholar
• IWAHI T, OKONOGI K, YA.MAZAKI T, SHIKI S, KONDO M, MIYAKE A, IMADA A: In vitro and in vivo activities of SCE-2787, a new parenteral cephalosporin with broad antibacterial spectrum. Antimicrob. Agents Chemother. (1992) 36:1358–1366.
   Google Scholar
• IWAMOTO T, SAICAM. OTO K, YAMASHITA M, EZAKI M, HASHIMOTO S, FURUTA T, OKUHARA M, KOHSAKA: FR901379, a novel antlfungal antibiotic Program and Abstracts of the 33rd Interscience Conference on Antimicro-bial Agents and Chemotherapy, New Orleans, Louisiana, 199 Abstr. 371. FR901379 showed a survival ED50 in a mouse disseminated candidi-asis model of 2.7 mg/kg. FR901381 and FR901382 were less effective.
   Google Scholar
• IWATA K, YAGI A, SATOI S, TAKADA M, HAYASHI M, ASANO K, MATSUDA T: In vitro studies of aculeacin A, a new antifurtgal antibiotic. J. Antibiot. (1977) 30:203–209.
   Google Scholar
• JABARIT-ALDIGHIERI N, TORRES H, RAOULT D: Suscepti-bility of Rickettsia conori, R. rickettsii, and Coxiella burned' to P0127,391, P0131,628, pefloxacirt, oflox-acin, and ciprofioxacin. Antimicrob. Agents Chemother. (1992) 36:2529–2532.
   Google Scholar
• JOHNSON DM, JONES RN: Antibacterial activity of the investigational oral and parenteral cephalosporin BK-218. Eur.J. Clin. Microbiol, Infect. Dis. (1992) 11:181–188.
   PubMed Web of Science ®Google Scholar
• JOHNSON JH, COOPER MA, ANDREWS JM, WISE R: Phar-macolcinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob. Agents Chemother. (1992) 36:2444–2446.
   PubMed Web of Science ®Google Scholar
• JONES RN, ERWIN ME, BARRETT MS, BRIGGS BM, JOHNSON DM: In vitro activity of RU-29246: the meta-bolite of a new HR-916 cephalosporin ester. Diagn. Microbiol. Infect. Dis. (1991) 14:473–483.
   PubMed Web of Science ®Google Scholar
• JONES RN, BARRY L, THE COLLABORATIVE ANTIMICRO-BIAL SUSCEP I iBILITY TESTING GROUP: Ceftibuten (7432-5, SCR-39720): comparative antimicrobial activity against 4735 clinical isolates. ll-lactamase stability and broth microdilution quality control guidleines. Eur. J. Clin. Infect. Dis. (1988) 7:802.
   PubMedGoogle Scholar
• JONES RN, ERWIN ME: In vitro evaluation of Ro O9-1227, a novel catechol-substituted cephalosporin. Antimicrob. Agents Chemother. (1992) 36:233–238.
   PubMed Web of Science ®Google Scholar
• JONSSON M, WALDER M, FORSGREN A: First clinical isolate of highly fluoroquinolone-resistant Escbericbia coil in Scandinavia. Eur. j Clin. Microbiol. Infect. Dis. (1990) 9:851–853.
   PubMed Web of Science ®Google Scholar
• KAATZ GW, SEO SM, LAMP KC, BAILEY EM, RYBAK MJ: CI-960, a new fiuoroquinolone, for therapy of experi-mental ciprofloxacin-susceptible and -resistantStapby-lococcus aureus endocarditis. Antimicrob. Agents Chemother. (1992) 36:1192-1197. A detailed study describing the activity of clinaflortacin in an endocarditis model.
   Google Scholar
• KAISER GV, GORMAN M, WEBBER JA: Cefamandole, a review of chemistry and microbiology. J/nfect Dis (1978) 137 (Suppl.) S–10–16.
   Google Scholar
• KAMACHI H, OKA M, NARITA Y, IIMURA S, ABURAKI S, YAMASHITA H, TOMATSU K, OKUMURA J, NAITO T: Synthesis of a new series of cephalosporins having 3-substituted anataonio-1-propenyl group as the C-3 side chain. J. Antibiot. (1990) 43:533–543.
   PubMed Web of Science ®Google Scholar
• ICAMIMURA T, MATSUMOTO Y, OKADA N, MINE Y, NISHIDA M, GOTO S, KUWAHARA S. Comparison of antibacterial activity of new cephalosporin, cefti-zoxime (FK 749) with other cephalosporins. J. Antibiot-ics(1979) 32:1319–1327.
   Google Scholar
• KAMIYA T, NAITO T, KAI Y, KOMATU Y, SASHO M, SATO N, NAKAMURA T, NEGI S, MOCHIDA Y, YAMAUCHI H. Synthesis and structure-activity relationships of fluoromethoxyirnino containing cephems - E–1077, a 252 novel parenteral cephem. 30th Intersci. Conf Antimicrob. Agent Chemother., Atlanta 1990 Abstr. 447.
   Google Scholar
• KANEKO A, SASAKI J, MORISHIMA T: Bacteriological evaluation of organisms isolated from a collaborative clinical study of cefditoren pivoxil (ME-1207). Oral Then Pharmacol. (1992) 11:124.
   Google Scholar
• KATO N, WATANABE K, KATO H, TANAKA K, TANAKA Y, UENO K: Comparative in vitro activity of DU-6859a, a new quinolone, against anaerobic bacteria. 33rd Inter-science Conference on Antimicrobial Agents and Chemother-apy, New Orleans, (1993), Abstr. 990.
   Google Scholar
• KATO N, KATO H, TANAKA Y, BANDOH K, WATANABE K, UENO K: The in vitro activity of 5-1006, the active form of a new oral cephalosporin, S-1108, against anaerobic bacteria. Chemotherapy (Tokyo) (1993) 41:40–49.
   Google Scholar
• KATO N, KATO H, TANAKA Y, BANDO K, WATANABE K, UENO K. In vitro activity of FK 037, a new parenteral cephalosporin against anaerobic bacteria. Antimicrob. Agents Chemother. (1993) 37:957–961.
   PubMed Web of Science ®Google Scholar
• KATSU K, KITOH K, INOUE M, MITSUHASHI S. In vitro antibacterial activity of E-0702, a semi-synthetic cepha-losporin. Antimicrob. Agents Chemother. (1982) 22:181–185.
   PubMed Web of Science ®Google Scholar
• KELLER-JUSLEN C, KUHN M, LOOSLI H-R, PECHTER TJ, WEBER HP, WARTBURG A: Struktur des cyclopeptid-an-tibiotikums SL 7810 (= echinocandin B). Tetrahedron Lett. (1976) 4147–4150.
   Google Scholar
• Describes the structure determination, and crystal structure of echi-nocandin B and several heavy-atom derivatives.
   Google Scholar
• KENNY GE, CARTWRIGHT FD: Susceptibilities of Myco- plasma bominis, M. pneumoniae, and Ureaplasma ure-aticum to a new quinoione, OPC–17116.
   Google Scholar
• Antimicrob. Agents Chemother. (1993) 37:1726–1727.
   Google Scholar
• KESSLER H, KUrSCHER B, MAGER G AND GRELL E: Syn-these des streptogramin-B-analogen cyclodepsipeptid cycloRBoc)Ser-D-Abu-Pro-(Me)Phe-Pip-Phg-0]. Liebigs Ann.Chem. (1983) 1541–1550.
   Google Scholar
• KHARDORI N, NGUYEN H, STEPHENS LC, KALVAKUNTLA L, ROSENBAUM B, BODEY GP: Comparative efficacies of cilofungin (Ly121019) and amphotericin B against dis-seminated Candida albicans infection in normal and granulocytopenic mice. Antimicrob. Agents Chemother. (1993) 37:729-736. A study comparing survival and kidney clearance in normal and granulocytopenic mice with cilofungin and amphotericin B. Drugs were administered ip. Cilofungin dosed bid at 15–25 mg/kg/day for ten days was equivalent to or better than amphotericin dosed qd at 1 mg/kg /day.
   Google Scholar
• KIMURA M, KISHIMOTO T, NIKI Y, SOEJIMA R: In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents. Antimicrob. Agents Chemother. (1993) 37:801–803.
   PubMed Web of Science ®Google Scholar
• KIMURA Y, YASUDA N: Polymyxin acylase: purification and characterization, with special reference to broad substrate specificity. Agric . Biol. Chem. (1989) 53:497–504.
   Web of Science ®Google Scholar
• KIMURA Y, NAKASHIMIZU H, MURAKAMI K, KOIKE M, NISHIUCHI M: S-1090, a new oral cephalosporin: IL Pharmacokinetics in animals. 32nd Interscience Confer-ence on Antimicrobial Agents and Chemotherapy Anaheim (1992) Abstr. 184.
   Google Scholar
• KING A, BOOTHMAN C, PHILLIPS I: The in vitro activity of PD127391, a new quinolone. J. Antimicrob. Chemother. (1988) 22:135–141.
   PubMed Web of Science ®Google Scholar
• KISICKI JC, et al.: Multiple-dose pharmacokinetics and safety of rufloxacin In normal volunteers. Antimicrob. Agents Chemother. (1992) 36:1296–1301.
   PubMed Web of Science ®Google Scholar
• KITANO K, NARA K, NAKAO Y: Screening of beta-lactam antibiotic using a mutant of Pseudomonas aeruginosa. Jap J. Antibiotics (1977) 30(Suppl.) S–239–247.
   Google Scholar
• KITCHEN VS, SAVAGE M, HARRIS JRW: Candida-albicans resistance in AIDS. J. Infect. (1991) 22:204–205.
   PubMed Web of Science ®Google Scholar
• KITZIS MD, LIASSINE N, FERRE B, GUTMANN L, ACAR JF, GOLDSTEIN F: In vitro activities of 15 oral 13-lactams against Klebsiella pneumoniae harboring new ex-tended spectrum 13-lactamases. Antimicrob. Agents Chemother. (1990) 3 4: 1783–1786.
   Google Scholar
• Good comparison of different susceptibilities to I3-lactamases.
   Google Scholar
• KOBORI T, FUJITA M, YAMAMOTO R, HIYAMA T, KONDO K, NUMATA K. NAGATE T, HANADA K: SC-002, a new cephalosporin: synthesis and in vitro antibacterial ac-tivity. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy Anaheim (1992) Abstr. 190.
   Google Scholar
• KOIKE M, NII S, MORITA S, AKIYAMA H, ODOMI M: OPC-17116, a new quinolone: pharmacokinetics and metabolism in healthy volunteers. 31st Interscience Con-ference on Antimicrobial Agents Chemotherapy, Atlanta, (1991), Abstr. 1482.
   Google Scholar
• KOLB A, BUSBY S, BUC H, GARGES S, ADHYA S: Tran-scriptional regulation by cAMP and its receptor protein. Annu Rev Biochem (1993) 62:749–795.
   PubMed Web of Science ®Google Scholar
• KOMIYA I, YOSHIDA T, MATSUMOTO T, YAMAMOTO Y, SAKAGAMI K, ATSUMI K, NISHIO M, KAZUNO Y, FUKATSU S, MITSUHASHI S: A novel cephalosporin, ME-1207 - pharmacokinetic properties. 25th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy Minneapo-lis (1985) Abstr. 583.
   Google Scholar
• KORTEN U, MURRAY BE: Impact of the fluoroquinolones on gastrointestinal flora. Drugs (1993) 45 (Suppl. 3):125–133.
   Google Scholar
• KORTEN U, TOMAYKO JF, MURRAY BE: DU-6859a, a new fluoroquinolone agent: comparative in vitro activity against Gram-positive cocci. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, (1993), Abstr. 985.
   Google Scholar
• KOSUGE K, WADA K, et al.: Phase I study of AM-1155. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, (1992), Abstr. 1003.
   Google Scholar
• KOUPAL LR, WEISSBERGER B, SHUNGU DL, WEINBERG E, GRADEBUSH H: Quarternary heterocyclylamino tams . II. The in vitro antibacterial properties of L 640876 a new type of f3-lactam antibiotic. J. Antibiotics (1983) 36:47–53.
   Google Scholar
• KUROKAWA N, O1IFUNE Y: Total synthesis of echino-candins. 2. Total synthesis of echinocandin D via effi-cient peptide coupling reactions./ Am. Chem. Soc. (1986) 108:6043–6045.
   Google Scholar
• First total synthesis of an echinocandin natural product.
   Google Scholar
• KUROKAWA N, OHFUNE Y: Synthetic studies on antifun-gal cyclic peptides, echinocandins - Stereoselective total synthesis of echinocandin D via a novel peptide cou-pling. Tetrahedron (1993) 49:6195–6222.
   Web of Science ®Google Scholar
• Full account of the JACS communication. Attempts to prepare echinocandin B were unsuccessful.
   Google Scholar
• KURTZ MB, MARRINAN J, ONISHI J, DREIKORN S, HEATH IB, DOUGLAS C: A morphological susceptibility assay to rank pneumocandin analogs against AspergiUus sp. Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993 Abstr. 352. Morphological effects of pneumocandin derivatives on Aspergillus species was described.
   Google Scholar
• LABRO MT, BRYSKIER A: imrnunomodulating properties of new cephalosporins: a preliminary cLIssificallon. Chimiotherapia (1987) 6 (Suppl 2):219–221.
   PubMedGoogle Scholar
• LAKINGS DB, FRIIS JM, BROWN RJ, ALLEN HR: Pharma-cokinetics of cefpimizole in normal humans after sin-gle- and multiple-dose intravenous infusions. Antimi-crob. Agents Chemother. (1984) 26:802–806.
   PubMed Web of Science ®Google Scholar
• LALANDE V, et al.: Powerful bactericidal activity of spar-floxacin against Mycobacterium tuberculosis in mice. Anttmicrob. Agents Chemother. (1993) 37:407–413.
   Google Scholar
• LAM nric, ZINK DL, SMITH AJ, LEE NW, FREEDMAN S, SALVATORE MJ: New virginiamycin M1 derivatives: Syn-thesis, cholecystokinin binding inhibitory and antimi-crobial properties. J. Antibiotics (1992) 46(4):623–630.
   Web of Science ®Google Scholar
• LAM YKT, BOGEN D, CHANG RS, FAUST KA, HENSENS OD, ZINK DL, SCHWARTZ CD, ZITANO L, GARRITY GM, GAGLIARDI MM, CURRIE SA, WOODDRUFF FIB: Novel and potent gastrin and brain cholecystokinin antagonist from Streptontyces olivaceus. Taxonomy, fermenta-tion, isolation, chemical conversions, and physico-chemical and biochemical properties. J. Antibiotics (1990) 44(6):613–625.
   Google Scholar
• LATTRELL R, BLUMBACH J, DeRCKHEIMER W, FEHLHABER HW, FLEISHMANN K, KIRRSTErihR R, MENCKE B, SCHE-UNEMANN KR, SCHRINNER E, SCHWAB W, SEEGER K, SEIBERT G, WIEDUWILT M. Synthesis and structure-ac-tivity relationships in the cefpirome series L 713[242-aminothiazol-4-y1)-(Z)-2-oxyltninoacetamidol-3-(subst ituted-l-pyridinio)methyl]ceph-3-em-4-carboxylates. J. Antibiotics (1988) 41:1374–1394.
   Google Scholar
• LE NOC P, BRYSKIER A, LE NOC D: Activité antibac-térienne in vitro d'une nouvelle céphalosporine: le cefpirome (BR 810). Comparison avec la ceftriaxone, le céfotaxime, le latamoxef et la ceftazidime. Pathol. Biol. (1986) 34:567–571.
   Google Scholar
• LECLERCQ R, NANTAS L, SOUSSY CJ, DUVAL J: Activity of RP 59500, a new parenteral semisynthetic strepto-gramin, against staphylococci with various mecha-nisms of resistance to macrolide-lincosamide- strepto-gramin antibiotics. J. Antimicrob. Chemother. (1992) 30(Suppl. A):67–76.
   Google Scholar
• LEE BL, PADULA AM, KIMBROUGH RCJONES SR, CHATS-SON RE, MILLS J, SANDE MA: infectious complications with respiratory pathogens despite ciprofloxacin ther-apy. N. Engl.J. Med. (1991) 325.520–521.
   PubMed Web of Science ®Google Scholar
• LEFEURE JC, BAURIAUD R, GAUBERT E, ESCAFFRE MC, LARENG MB: In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens. Chemother. (1992) 38:303–307.
   PubMed Web of Science ®Google Scholar
• LEROY A, LEGLTY F, BORSA F, SPENCER GR, FILLASTRE JP, HUMBERT G: Pharmacokinetics of ceftazidime in nor-mal and uremic subjects. Antimicrob. Agent Chemother, (1984) 25:638–642.
   PubMed Web of Science ®Google Scholar
• LEWIN C, DOHERTY C, GOVAN J: In vitro activities of meropenem, PD127391, PD131628, ceftazidime, chlora.mphenicol, co-trimaxazole, and ciprofloxacin against Pseudomonas cepacia. Antimicrob. Agents Chemother. (1993) 31:123–125.
   Google Scholar
• LEWIN CS, MORRISSEY I, SMITH JT: The bactericidal activity of sparfloxacin. J. Antimicrob. Chemother. (1992) 30:625–632.
   PubMed Web of Science ®Google Scholar
• LEWIN CS: Antibacterial activity of a 1,8-naphthyridine quinolone, PD131628. J. Med. Microbiol. (1992) 36:353–357.
   PubMed Web of Science ®Google Scholar
• LIMBERT M, ISERT D, KLESEL N, MARKUS A, SEEGER K, SEIBERT G, SCHRINNER E: Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin. Antimi-crob. Agents Chemother. (1991) 35:14–19.
   PubMed Web of Science ®Google Scholar
• LYMAN CA, WALSH TJ: Systemically administered anti ungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs (1992) 44:9–35.
   Google Scholar
• An excellent review of current antifungal agents useful for systemic infection and of experimental agents in development. The review covers the polyenes, flucytosine, azoles and other investigational compounds.
   Google Scholar
• MACKAY JA, HARDING SM, PALMER JL, EVANS GL. Volun-teer studies with GR 69153, a novel cephalosporin. 29th Intersci. Conf Antimicrob. Agent Chemother., Houston 1989 Abstr. 159.
   Google Scholar
• MAEJIMA T, INOUE M, MITSUHASHI S: In vitro antibacte-rial activity of KP-736, a new cephem antibiotic. Antimi-crob. Agents Chemother. (1991) 35:104–110.
   PubMed Web of Science ®Google Scholar
• MAHAN MJ, SLAUCH JM, MEKALANOS JJ: Selection of bacterial virulence genes that are specifically induced in host tissues. Science (1993) 259:686–688.
   PubMed Web of Science ®Google Scholar
• Describes a novel technique to identify genes expressed exclusively in vivo.
   Google Scholar
• MARSHALL SA, JONES RN: In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone. Antimicrob. Agents Chemother. (1993) 37:2747–2753.
   PubMed Web of Science ®Google Scholar
• MARTINELLI E, ZERILLI LF, VOLPE G, PAGAN! H, E CARELLI B: New antibiotics fromActinoplanes strains. Structure of A 17002 C. J. Antibiotics (1979):108–114.
   Google Scholar
• MASS L, MALERCZYK V, VERHO M, HADJU P, SEEGER K, KLESEL N. Dose linearity testing of intravenous cefpi-rome (HR810), a novel cephalosporin derivate. Infection (1987) 15:202–206.
   PubMed Web of Science ®Google Scholar
• MASUREKAR PS, FOUNTOULAKIS JM, HALLADA TC, SOSA MS KAPLAN L: Pneumocandins from Zalerion arbori-cola H. Modification of product spectrum by mutation and medium manipulation. J. Antibiot. (1992) 45:1867–1874.
   Google Scholar
• MATSUBARA T, OTSUBO S, OGAWA A: Effects of 6315 S fktrnoxef) on the alcohol-metabolizing system in rats. Chemotherapy (Tokyo) (1987) 35 (Suppl 1):460–469.
   Google Scholar
• MATSUMATO M, YOKOMI K, YASAMURA K, TUBOUCHI TSUJI K, TAMAOKA H, KIKUCHI H: In vitro and in vivo activities of OPC-20000, a novel parenteral broad spec-trum 2-oxa-lsocephem antibiotic. 33rd Interscience Con-ference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 886.
   Google Scholar
• MATSUMOTO M, KOJIMA K, NAGANO H, MATSUBARA S, YOKOTA T: Photostability and biological activity of fluoroquinolones substituted at the 8-position after uv Irradiation. An timicrob . Agents Chemother. (1992) 36:1715–1719.
   PubMed Web of Science ®Google Scholar
• An interesting study which attempts to draw correlations between the photo degradation of fluoroquinolone analogs with in vitro cytotoxicity.
   Google Scholar
• MATSUMOTO Y, MATSUDA S, TEGOSHI T: Yeast glucan In the cyst wall of Pneumocystis carinii. j Protozool. (1989) 36:21S. This disclosure was the first that indicated the cyst wall of P. carinii contained P-(1,3)-glucan.
   Google Scholar
• MATSUMOTO Y, YAMADA M, AMAGAI T: Yeast &can of Pneumocystis carinii cyst wall: An excellent target for chemotherapy. J. Protozool. (1991) 38:6S-7S. Aculeacin A was efficacious at 2 or 10 mg/kg qd for two weeks in a rat P. carinii pneumonia model.
   Google Scholar
• MATSUURA S, YAMANO Y, NAKASHIMIZU H, MATSUBARA T, KOBAYASHI F, KUWAHARA 5: 8–1108, a new oral cephem: absorption and efficacy. 29th Interscience Con-ference on Antimicrobial Agents and Chemotherapy Houston (1985) Abstr. 369.
   Google Scholar
• MAITINA R, COCUZZA CE, CESANA M, BONFIGLIO G: In vitro activity of a new quinolone, rufloxacin, against nosocomial isolates. Chemother. (1991) 37:260–269.
   PubMed Web of Science ®Google Scholar
• MATTINA R, COCUZZA CE, CESANA M: Rufioxacin once daily versus ofloyeacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Infection (1993) 21:106–111.
   PubMed Web of Science ®Google Scholar
• MEIS JF, DONNELLY JP, HOOGKAMP-KORSTANJE JA, DE PAUW BE: Aspergillus-fumigatis pneumonia in ne-tropenic patients during therapy with fluconazole for Infection due to Candida species. Clin. Inf Dis. (1993) 16:734–735.
   PubMed Web of Science ®Google Scholar
• MENDES P, MEYER BH, MÜLLER FO, SCHOLL T, LUUS H, DE LA REY N: Pharrnacokinetics of cefdaloxime pentemdl tos Bate (HR916 K) after a single oral dose in healthy volunteers. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy Anaheim (1992) Abstr. 189.
   Google Scholar
• MIKAMO H, TAMAYA T, HACHIYA S, SATOH M: Effects of a novel cephalosporin E1077 on intrauterine infections In a newly designed rat modeL 33rd Interscience Confer-ence on Antimicrobial Agents and Chemotherapy New Or-leans (1993) Abstr. 869.
   Google Scholar
• MILLS J, MASUR H: AIDS-related infections. Scientific American (1990) August:50–57.
   Google Scholar
• MINE Y, KAMIMURA T, WATANABE Y, TAWARA S, MATSU-MOTO Y, SFIIBAYAMA F, KIKUCHI H, TAKAYA T, KUWA-HARA S: In vitro antibacterial activity of FK482, a new orally active cephalosporin. J. Antibiot. (1988) 41:1873–1887.
   PubMed Web of Science ®Google Scholar
• MINE Y, YOKOTA Y, WAKAI Y, KAMIMURA T, TAWARA S, SHIBAYAMA F, KIKUCHI FL KUWAHARA S: In vivo an-tibacterial activity of FK482, a new orally active cepha-losporin_ J. Antibiot. (1988) 41:1888–1895.
   Google Scholar
• MINE Y, WATANABE Y, SAKAMOTO H, HATANO K, KUNO K, HIGASHI Y, KAMIMURA T, MATSUMOTO Y, TAWARA S, MATSUMOTO F, et al.: In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cepha-losporin_ J. Antibiot. (1993) 46:71–87.
   Google Scholar
• MINE Y, SAKAMOTO H, KAMIMURA T, WATANABE Y, MATSUMOTO Y: FK-518, a new parenteral antipseudo-monal cephalosporin U. In vitro antibacterial activity. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy Atlanta (1990) Abstr. 455.
   Google Scholar
• MINE Y, SAKAMOTO H, KAMIMURA T, WATANABE Y, TAWARA S, KUWAHARA S: FK-518, a new parenteral antipseudomonal cephalosporin M. In vivo antibacte-rial activity. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy Atlanta (1990) Abstr. 456.
   Google Scholar
• MIRANDA AG, WANGER AR, SINGH KU, MURRAY BE: Comparativebt vitro activity of PD127391, a new fluoro-quinolone agent, against susceptible and resistant clini-cal isolates of Gram-positive coccL Antimicrob. Agents Chemother. (1992) 36:1325–1328.
   PubMed Web of Science ®Google Scholar
• MITSCHER LA, DEVASTHALE P, ZAVOD R: Structure-activ-ity relationships. In: Quinolone Antimicrobial Agents, 2nd Edition (1993) Hooper DC, Wolfson JS (Eds), American Society for Microbiology, Washington, DC.
   Google Scholar
• MIYAKE A, YOSHIMURA Y, YAMAOKA M, NISHIMURA T, HASHIMOTO N, IMADA A. Synthesis and structure-activ-ity relationships of 3-condensed azolium methyl cepha-losporins including SCE 2787, a new parenteral cepha-losporin. 29th Intersci. coq Antimicrob. Agent Chemother., Houston 1989 Abstr. 486.
   Google Scholar
• MIYAZAKI S, MIYAZAKI Y, TSUJI A, NISHIDA M, GOTO S: In vitro and in vivo studies of MX1228, a new parenteral cephalosporin with potent activity against Pseudo-monas aeruginosa. Antimic rob. Agents Chemother. (1991) 35:1245–1246
   PubMed Web of Science ®Google Scholar
• MIZOGUCHI J, SAITO T, MIZUNO K, HAYANO K: On the mode of action of a new antifungal antibiotic, aculeacin A: Inhibition of cell wall synthesis in Saccbaromyces cerevisiae. Antibiot. (1977) 30:308–313.
   Google Scholar
• MIZIJNO K, YAGI A, SATOI S, TAKADA M, HAYASHI M, ASANO K, MATSUDA T: Studies on aculeacin. I. Isolation and characterization of aculeacin A. J. Antibiot. (1977) 30:297–302.
   PubMed Web of Science ®Google Scholar
• MOERMAN MC, ANTEUNIS MJO: Unique 1'-0 Boc protec-tion of virginiamycin Sand resulting resistance against sodium hydroxide. Bull. Soc. Chim. Beiges (1991) 100:647–651.
   Google Scholar
• MOERMAN MC, ANTEUNIS MJO: Partial synthesis of five analogues of the peptido lactone Virginiamycin Si, modified in the fifth and/or sixth position ([Xxx51-VS1 with Xxx = Ala, Asp, Mn and Lys and [A1a5,Gly6]-VS1). Int. J. Peptide Protein Res. (1993) 41:102–117.
   PubMedGoogle Scholar
• MONTAY G, et al.: Dose-dependent pharrnacokinetic study of sparfloxacin in healthy young volunteers. 30th Interscience Conference on Antimicrobial Agents and Che-motherapy, Atlanta, (1990), Abstr. 1248.
   Google Scholar
• MOON S-S, CHEM JL, MOORE RE, PAITERSON GML: Calo-phycin, a fungicidal cyclic decapeptide form the terres-trialblue-green algaCalotbrixfusca. J. O. Chem. (1992) 57:1097–1103.
   Google Scholar
• MORIN RB, JACKSON BG, FLYNN EH, ROESKE RW: Chem-istry of cephalosporin antibiotics M. Chemical correla-tion of penicillin and cephalosporin antibiotics. J Am Chem Soc (1962) 84:3400–3401.
   Web of Science ®Google Scholar
• MORINO A, OKLTYAMA Y, MOMOTA K, OHYABU M, USHI-MARU K: Pharmacokinetics of NM441, a new quinolone, in laboratory animals. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, (1992), Abstr. 659.
   Google Scholar
• MUDER RR, BRENNEN C, GOETZ AM, WAGENER MM, REIS JD: Association with prior fluoroquinolone therapy of widespread ciprofloxacin resistance among Gram-
   Google Scholar
• SO negative isolates in a Veterans Affairs medical center. Antimicrob. Agents Chemother. (1991) 35:256–258.
   PubMedGoogle Scholar
• MUKHOPADHYAY T, GANGULI BN: Mulundocandin, a new lipopeptide antibiotic. IL Structure elucidation. J. Antibiot. (1986) 40:281–289.
   Web of Science ®Google Scholar
• MUKHOPADHYAY T, ROY K, BHAT RG, SAWANT SN, BLUMBACH J, GANGULI BN, FEHLHABER HW, KOGLER H: Deoxymulundocandin - A new echinocandin type anti-fungal antibiotic. J. Antibiot. (1992) 45:618–623.
   PubMed Web of Science ®Google Scholar
• MURAKAMI K, KUBOTA T, SASAKI S, MIWA H, KIMURA Y, KOMATSU Y, YOSHIDA T: S-1090, a new oral cepha-losporin; L Antibacterial activity. 32nd Interscience Con-ference on Antimicrobial Agents and Chemotherapy Anaheim (1992) Abstr. 183.
   Google Scholar
• MURATANI T, INOUE M, MITSUHASHI S: In vitro activity of T-3761, a new fluoroquinolone. Antimicrob. Agents Chemother. (1992) 36:2293–2303.
   PubMed Web of Science ®Google Scholar
• MURRAY BE: 13-lactamase producing enterococcL An-timicrob. Agents Chemother. (1992) 36:2355–2359.
   PubMed Web of Science ®Google Scholar
• NAGARAJAN R, BOECK LD, GORMAN M, HAMILL RI, HIG-GENS CE, HOEHN MM, STARK WM, WHITNEY JG: f3-1acta.m antibiotics from Streptomyces. J Am Chem Soc (1971) 93:2308–2310.
   PubMed Web of Science ®Google Scholar
• NAITO T, ABURAKI S, KAMACHI H, NARITA Y, OKUMURA J, KAWAGUCHI H. Synthesis and structure-activity rela-tionships of a new series of cephalosporins, BMY-28142 and related compounds. J. Antibiotics (1986) 39:1092–1107.
   PubMed Web of Science ®Google Scholar
• NAJVAR L, ALBERT M, BOCANEGRA R, LUTHER M, COLUM-BUS A, GRAYBILL J: Efficacy of LY295337 (LY) in a rat model of pulmonary aspergillosis (PA) and cryptococ-cal meningitis (CM). Program and Abstracts of the 33nd Interscience Conference on Antimicrobial Agents and Che-motherapy, New Orleans, Louisiana, 1993, Abstr. 366. This study showed that LY295337 failed in the PA model and displayed poor activity in the CM model.
   Google Scholar
• NAKAMURA S, et al.: In vitro and in vivo antibacterial activities of AT-4140, a new broad spectrum quinolone. Antimicrob. Agents Chemother. (1989) 33:1167–1173.
   Google Scholar
• NAKAMURA S, KUROBE N, OHUE T, HASHIMOTO M, SHIMIZU M: Phannacokinetks of a novel quinolone,AT-4140, in animals. Antimicrob. Agents Chemother. (1990) 34:89–93.
   PubMed Web of Science ®Google Scholar
• NAKANE T, IYOBE S, MITSUHASHI S: Antibacterial activ-ity of DU-6859a, a new quinolone. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, (1993), Abstr. 978.
   Google Scholar
• NAKANISHI N, YOSHIDA S, WAKEBE H, INOUE M, YAMA-GUCHI T, MITSUHASHI S: Mechanisms of clinical resis-tance to fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. (1991) 35:2562–2567.
   PubMed Web of Science ®Google Scholar
• NAKASHIMA M, UEMATSU T, KOSUGE K, TAI M, NAKA- GAWA S, TSUDA H: Phannacoldnetics and safety of T-3761 in healthy volunteers. 32nd Interscience Confer-ence on Antimicrobial Agents and Chemotherapy, Anaheim, (1992), Abstr. 656.
   Google Scholar
• NAKASHIMA M, UEMATSU T, KANAMARU M, OKAZAKI O, HAKUSUI H: Phase I study of levofloxacin. Jpn. J. Clin. Pharmacol. Ther. (1992) 23:515–520.
   Google Scholar
• NAKASHIMA M, UEMATSU T, NAKANO M, KOSUGE K, TANAKA M, HAKUSUI Pharrnacokinetics and safety Investigation of a new fluoroquinolone, DU-6859a, in healthy male volunteers. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, (1993), Abstr. 1004. NAKASHIMA M, MATSUNO S, YOSHIDA T, KIMURA Y, OGUMA T, ISHII H: Pharmacokinetics and safety of S-1108 in healthy volunteers. 29th Interscience Conference on Antimicrobial Agents and Chemotherapy Houston (1989) Abstr. 370.
   Google Scholar
• NAKASHIMA M, IMOTO H, KIMURA Y, SASAKI S, OGUMA T, YAMAMATO S: S-1090, a new oral cephem antibiotic pharmacokinetics in humans. 33rd Interscience Confer-ence on Antimicrobial Agents and Chemotherapy New Or-leans (1993) Abstr. 416.
   Google Scholar
• NAKASHIMA M, HASHIMOTO H, TAKIGUCHI Y, MIZUNO A, WATANABE K, UENO K, YOSHIZUMI K: Phase I- L 105. Chemotherapy (Tokyo) (1986) 34 (Suppl. 3):133–143.
   Google Scholar
• NAKASHIMA M, UEMATSU T, NAGASHIMA S, HIRASAWA T, TOMONO Y, OHNO T, OKANO K, MORISHITA N. Phannacoldnetics and safety of E-1077, a novel paren-teral cephem antibiotic, in healthy volunteers. 31st Intersci. Conf Antimicrob. Agent Chemother., Chicago 1991 Abstr. 848.
   Google Scholar
• NAKASHIMA M, UEMATSU T, KANAMARU M, UENO K, SETOYAMA T, TOMONO Y, OHNO T, OKANO K, MORISHITA N. Phase! study of E-1040, a new parenteral cephem antibiotic. J. Clin. Pharmacol (1989) 29:144–150.
   Google Scholar
• NAKASHIO S, HORT S, YANAGAWA A, SHIMADA J: Com-parative antimicrobial activity of NM394, a new qui-nolone compound against clinical isolates. 32nd Inter-science Conference on Antimicrobial Agents and Chemotherapy, Chicago, (1992), Abstr. 658.
   Google Scholar
• NAKATA, K, MAEDA, H, FUJI, A, ARAKAWA, S, UMEZU, K, KAMIDONO, S: In vitro and in vivo activities of sparflox-acin, other quinolones, and tetracyclines against Chlanrydia trachomatis. Antimicrob. Agents Chemother. (1992) 36:188–190.
   PubMed Web of Science ®Google Scholar
• NAORA K, KATAGIRI Y, IWAMOTO K, TANAKA K, YAMA-GUCHI T, SEKINE Y: Effect of fenbufen on the pharrna-cokinetics of sparfloxacin in rats. J. Antimicrob. Chemother. (1992) 30:673–683.
   PubMedGoogle Scholar
• NARASIDA M, ONOUE H, NAGATA W: Synthetic studies on plactam antibiotics - Part 5 - A synthesis of 73-acy-lamino-3-methyl-1-oxadethia-3-cephem-4-carboxylk add. Heterocycles (1977) 7:839–849.
   Web of Science ®Google Scholar
• NARASIDA M, YOSHIDA T, OHTANI M, EZUMI K, TAKASUKA M: Synthesis and substituent effects on an-tibacterial activity, alkaline hydrolysis rates and infra-red absorption frequencies of some cephem analogues related to latamoxef (moxalactam). J. Med. Chem. (1983) 26:1577–1582.
   PubMed Web of Science ®Google Scholar
• NEGI S, YAMANAKA M, SUGIYAMA I, KOMATSU Y, SASHO M, TSURUOKA A, KAMADA A, TSUKADA I, HIRUMA R, KATSU K et al.: E1101, a new oral cephalosporin: I. Synthesis and structure activity relationships of 3-sub-stitued carcamoyloxymethyl cephems. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 894.
   Google Scholar
• NEU H: The crisis in antibiotic resistance. Science (1992) 257:1064–1072.
   PubMed Web of Science ®Google Scholar
• NEU HC, CHIN N, GU J: The in vitro activity of new streptogramins, RP 59500, RP 57669 and RP 54476, 357 tee lone and in combination. j, Antimicrob. Chemother. (1992) 30(Suppl. A):83–94.
   Google Scholar
• NEU HC, CHIN N-X: In vitro activity of S-ofloxacin. Antimicrob. Agents Chemother. (1989) 33:1105–1107.
   PubMed Web of Science ®Google Scholar
• NEU HC, CHIN NX: In vitro activity of CP-99,219, 7-(3-aza-bicyclo[3.1.01hexyflnaphthyridone. 32nd Inter-science Conference on Antimicrobial Agents and Chemother-apy, Anaheim, (1992), Abstr. 754.
   Google Scholar
• NEU HC, FANG W, GU J-W, CHIN N-X: In vitro activity of OPC-17116. An timicrob. Agents Chemother. (1992) 36:1310–1315.
   PubMed Web of Science ®Google Scholar
• NEU HC, SAHA G, CHIN NX: Comparative in vitro activity and O-lactamase stability of FK482: a new oral cepha-losporin. Antimicrob. Agents Chernother. (1989) 33:1795–1800.
   PubMed Web of Science ®Google Scholar
• NEU HC, SAHA G, CHIN NX: In vitro activity of ME1228, a new parenteral cephalosporin. Antimicrob. Agents Chemother. (1989) 33:1260–1267.
   PubMed Web of Science ®Google Scholar
• NEU HC, CHIN NX, HUANG HB: In vitro activity and P-lactamase stability of FK-037, a parenteral cepha-losporin. Antimicrob. Agents Chemother. (1993) 37:566–573.
   PubMed Web of Science ®Google Scholar
• NEU HC, SAHA G, CHIN N. In vitro activity of ME 1228, a new parenteral cephalosporin. Antimicrob. Agents Chemother. (1988) 33:1260–1267.
   Google Scholar
• NEU HC: Comparison of pharmacokinetics of cefaman-dole and other cephalosporin compounds. J. Infect. Dis. (1978) 137 (Suppl.) S–80–87.
   Google Scholar
• NEU HC: The crisis in antibiotic resistance. Science (1992) 257:1064–1073.
   PubMed Web of Science ®Google Scholar
• Discusses mechanisms of antibiotic resistance and the current trends in multiple resistance emergence.
   Google Scholar
• NEWTON GGF, ABRAHAM EP: Cephalosporin C, a new antibiotic containing sulfur and D-a- aminoadipic acid. Nature (1955) 175:548–556.
   PubMed Web of Science ®Google Scholar
• NIKAIDO H, ROSENBERG EY: Cir and Fiu proteins in the outer menbrane of Escbericia colt catalyze transport of monomeric catechols: study with beta-lactam antibiot-ics containing catechol and analogous groups. J. Bacte-riol. (1990) 172:1361–1367.
   PubMed Web of Science ®Google Scholar
• NIKAIDO H, LIU W, ROSENBERG EY: Outer membrane permeability and betalactamase stability of dipolar ionic cephalosporins containing methoxyimino substi-tuents. Antimicrob. Agents Chemother. (1990) 34:337–342.
   PubMed Web of Science ®Google Scholar
• NIKAIDO Fl, ROSENBERG EY. Cir and Flu proteins in the outer membrane of Escbericbia coil catalyze transport of monomeric catechols: study with 13-lactarn antibiot-ics containing catechol and analogous group. J. Bactv-riot. (1990) 172:1361–1367.
   PubMed Web of Science ®Google Scholar
• NISHIMURA K, YOSHIMI A, KITAGAWA M, HASHIZUME H, MURO H, KASAI M, HATANO S, KAKEYA N: KY-020, a new sweet tasting and orally absorbed pro-drug of cefti-zoxime; oral absorption and efficacy in animals. 30th Interscience Conference on Antimicrobial Agents and Che-motherapy Atlanta (1990) Abstr. 674.
   Google Scholar
• NISHINO T, OTSUKI M, NAKAMURA M: In vitro and in vivo antibacterial activities of sparfkmacin, a new difluori-nated quinolone. 30th Interscience Conference on Antimi-crobial Agents and Chemotherapy, Atlanta, (1990), Abstr. 1244.
   Google Scholar
• NISHINO T, OTSUK1 M, HOSAKA M: In vitro and in vivo antibacterial activities of AM-1155, a new 8-methoxy quinolone. Interscience Conference on Antimicrobial Agents Chemotherapy, Anaheim, (1992), Abstr. 1001.
   Google Scholar
• NIX DE, SYMONDS WT, PITLICK WH, O'CONNOR G, SCHENTAG JJ: Comparative bioavailability and pH de-pendency of tablet and solution formulations of OPC-17116. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, (1993), Abstr. 406.
   Google Scholar
• NOBLE HM, LANGLEY D, SIDEBOTTOM PJ, LANE SJ, FISHER PJ: An echinocandin from an endophytic Cryp- tosporiopsis sp. and Pezicula sp. in Pinus sylvestris and Fagus sylvatica. Mycol. Res. (1991) 95:1439–1440.
   Google Scholar
• Pneumocandin Ao is also produced by Cryptosporiopsis and Pezicula species
   Google Scholar
• NOMURA H, FUGONO T, HITAKA T, MINAMI I, AZUMA T, MORIMOTO S, MASUDA T: Semi-synthetic fl-lactam anti-biotics VD- New semi-synthetic cephalosporin derived from a-sulfonyl acetic acid. Heterocycles (1974) 2:67–72.
   Google Scholar
• NOMURA H, MINAMI I, HITAKA T, FUGONO T: Semi-syn-thetic fl-lactam antibiotics 8. Structure-activity relation-ships of a-sulfocephalosporins. J Antibiotics (1976) 29:928–936.
   Google Scholar
• NORD CE, HAGELBACK A: Susceptibility of anaerobic bacteria to PD131628. Eur. j Clin. Micro biol. Infect. Dis. (1992) 11:68–71.
   PubMed Web of Science ®Google Scholar
• NORD CE, LINDMARK A, PERSSON I: Comparative an-tibacterial activity of the new cephalosporin cefcanel against anaerobic bacteria. Eur. J. Clin. Microbiol. Infect. Dis. (1989) 8:550–556.
   PubMed Web of Science ®Google Scholar
• NOUGAYREDE A, BERTHAUD N, BOUANCHAUD DH: Post-antibiotic effects of RP 59500 withStapbylococcusaureus. J. Antimicrob. Chemother. (1992) 30(Suppl. A):101–106.
   Google Scholar
• NUMATA K, SUGITA K, AKASHI T, KANEDA Y, NAGATE T, HANADA K: SC-004, a new oral cephalosporin: In vivo antibacterial activity and oral absorption. 32nd Inter-science Conference on Antimicrobial Agents and Chemother-apy Anaheim (1992) Abstr. 191.
   Google Scholar
• O'CALLAGHAN CH, SYKES RB, GRIFFITHS A, THORNTON JE: Cef-uroxime, a new cephalosporin antibiotic activity in vitro. Antimicrob. Agents Chemother. (1976) 9:511–519.
   PubMed Web of Science ®Google Scholar
• O'CALLAGFIAN CH, ACRED P, HARPER PB, RYAN DM, KIRBY SM, HARDING SM. GR 20263, a new broad-spec-trum cephalosporin with anti-pseudomonal activity. Antimicrob. Agent Chemother. (1980) 17:876–883.
   PubMed Web of Science ®Google Scholar
• O'CALLAGHAN CH: Classification of cephalosporins by their antibacterial activity and pharmacokinetic prop-erties. J. Antimicrob. Chemother. (1975) 1 (Suppl):1–12.
   Google Scholar
• O'CALLAGHAN CI I: Description and classification of the newer cephalosporins and their relationships with the established compounds. J. Antimicrob. Chemother. (1979) 5:635–671.
   Google Scholar
• OCHAI M, MORITOMO A, MIYAWAKI T, MATSIIUSHITA Y, OKADA T, NATSUGARI H, KIDA M. Synthesis and struc-ture-activity relationships of 70-[2-(2-aminothiazol-4-yfiacetamido]cephalosporin derivatives V. Synthesis and antibacterial activity of 70-[2-(2-aminothiazol-4-y0-2-methoxyhninoacetamido] cephalosporin derivatives and related compounds. J. Antibiotics (1981) 34:171–185.
   Google Scholar
• OGASA T, SAITO H, HASHIMOTO Y, SATO K, HIRATA T: Synthesis and biological evaluation of optically active 3H-1-carbacephem compounds. Chem. Pharrrz. Bull. (1989) 37:315–321.
   PubMed Web of Science ®Google Scholar
• OHKAWA M, ORITO M, SUGATA T, SHIMAMURA M, SAWAKI M, NAKASHITA E, KURODA K, SASAHARA K: Pharmacokinetics of cefmetazole in normal subjects and in patients with impaired renal function. Antimi-crob. Agents Chemother. (1980) 18:386–389.
   PubMed Web of Science ®Google Scholar
• OHKAWA M, TOKUNAGA S, SUGATA T, SHIMAMURA M, OKASHO A, HIRANO S, MATSUI H: Pharmacokinetics of cefpiramide in healthy volunteers, patients with vari-ous degrees of renal dysfunction and patients on bernodialysis. Chemotherapy (Basel) (1989) 35:416–422.
   PubMed Web of Science ®Google Scholar
• OKITA T, IMAE K, HASEGAWA T, IIMURA S, MASLTYOSHI S, KAMACHI H, KAMEI H. Synthesis and antibacterial activity of cephalosporins having a catechol in the C3 side chain. Antibiotics (1990) 46:833–839.
   Google Scholar
• OKONOGI T, SHIBAHARA S, MURAI Y, YOSHIDA T, INOUYE S, KONDO S, CHRISTENSEN BG: Synthesis and antibacterial activity of novel 2-methyl-1-oxacepha-losporin. J. Antibiotics (1990) 43:357–371.
   PubMed Web of Science ®Google Scholar
• OKUDA J, OKAMOTO S, TAKAHATA M, NISHINO T: Inhibi-tory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistantStapbylococcus aureus. Antimi-crob. Agents Chemother. (1991) 35:2288–2293.
   PubMed Web of Science ®Google Scholar
• OKUMURA JS, ABURAKI H, KAMACHI H, NARITA Y, NAITO T, KAWAGUCHI H. New cephalosporin, BMY-28142 andrelated compounds: chemistry and preliminary evalu-ation. 23rd Intersci. Conf Antimicrob. Agent Chemother., Las Vegas (1983) Abstr. 576.
   Google Scholar
• OKUMURA Y: Directed biosynthesis of neoviridogrise-ins. In: Biochemistry of Peptide Antibiotics, (1990) Kleinkauf H and von Döhren (Eds), W de Gruyter, Berlin, N-Y, p365–378.
   Google Scholar
• ONO H, NOZAKI Y, KATAYAMA N, OKAZAKI H: Cephabicins, new cephem antibiotics of bacterial ori-gin L Discovery and taxonomy of the producing organ-isms and fermentation. J. Antibiotics (1984) 37:1528–1535.
   PubMed Web of Science ®Google Scholar
• OZAKI M, et al.: In vitro antibacterial activity of a new quinolone, NM394. Antimicrob. Agents Chemother. (1991) 35:2490–2495.
   Google Scholar
• OZAKI M, et al.: In vivo evaluation of NM441, a new thiazeto-quinoline derivative. An timicrob . Agents Chemother. (1991) 35:2496–2499.
   Google Scholar
• PACHE W, KELLER C, KUHN M: Cleavage of echinocandin B with polymyxin acylase liberating the fatty acid and reacylation of the peptide moiety. Experientia (1978) 34:1670–1671.
   Google Scholar
• PACHE W, DREYFUSS M, TRABER R, TSCHERTER H: Sporio-fungins, new antifungal antibiotics of the cyclopeptide group. In: Proceedings 13th International Congress of Che-motherapy, Vienna, Austria (1983):PS 4.8/3, Part 115, Abstr. 10.
   Google Scholar
• PACHOLOK C, LYNCH L, KROPP H, BARTIZAL K: In vitro evaluation of L-733,560, a new water soluble lipopep-tide hybrid of L-705,589 and L-731,373. Program and Abstracts of the 33rd Intetscience Conference on Antimicro-bial Agents and Chemotherapy, New Orleans, Louisiana, 1993 Abstr. 351. MFC90 determinations, time-kill curves and serum antagonism of pneumocandin derivatives were presented.
   Google Scholar
• PARIS JM, BARRIERE JC, SMITH C, BOST PE: The chemistry of pristinamycin. In: Recent Progress in the ChemicalSynthesis of Antibiotics (1990) Lukacs G, Ohno M (Eds), Springer Verlag, Berlin, Heidelberg, p183–248.
   Google Scholar
• An overview on the chemistry of streptogramins.
   Google Scholar
• /4. PARRY MF, PANZER KB, YUKNA ME: Quinolone resis- tance: susceptibility data from a 300-bed communityhospital. Am. J. Med. (1989) 87 (Suppl. 5A):125-15S.
   Google Scholar
• PASCULLE AW, LINDEN PK, MCDEVITT DA, WAGENER JL, MCKNIGHT JL, PAPAFRANGAS EA: Susceptibility of van-comycin-resistant Entero coccus faecium (VREF) to al-ternative antimicrobial agents singly and in combina-tion. 33rd International Conference On Antimicrobial Agents And Chemotherapy New Orleans, (1993), Abstr. 1060.
   Google Scholar
• PATEL HI, CHEN S, PARSONNET M, HACKMAN MR, seBROOKS MA, KONIKOFF J, KAPLAN SA: Pharmacokinet-ics of ceftriaxone in humans. Antimicrob. Agent Chemother. (1981) 20:634–641.
   PubMed Web of Science ®Google Scholar
• PATEL J, PACHUCKI CT, LENTINO JR: Synergy of levoflox-acin and oxacillin against quinolone-resistant Staphy-lococcus aureus, measured by the time-kill method. Antimicrob. Agents Chemother. (1993) 37:339–341.
   PubMed Web of Science ®Google Scholar
• PATTON DL, COSGROVE YT, KUO C-C, CAMPBELL LA: Effects of quinolone analog CI-960 in a monkey model of Chlamydia trachomatis salpingitis. Antimicrob. Agents Chernother. (1993) 37:8–13.
   PubMed Web of Science ®Google Scholar
• PAULFEUERBORN W, MULLER H-J, BORNER K, KOEPPE P, LODE H: Comparative phartnacokInetics and serum bactericidal activities of SCE-2787 and ceftazidime. An-timicrob. Agents Chemother. (1993) 37:1835–1841.
   PubMed Web of Science ®Google Scholar
• PAYA CV: Fungal infections in solid-organ transplanta-tion. Clin. Infect. Dis. (1993) 16:677–688.
   PubMed Web of Science ®Google Scholar
• PELAK BA, GILFTLLAN EC, WEISSBERGER B, GRADEBUSH H: Quarternary heterocyclylarnino fi-lactams: VI. In vitro and in vivo antibacterial properties of L-642946 and L-652813, a long acting cephem. J. Antibiotics (1987) 40:354–362.
   Google Scholar
• PEREZ-TRALLERO E, GARCIA-ARENZANA JM, JIMENEZ JA, PERIS A: Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. (1990) 9:905–906.
   PubMed Web of Science ®Google Scholar
• PERFECT JR: Antifungal prophylaxis - to prevent or not. Am.]. Med. (1993) 94:233–234.
   PubMed Web of Science ®Google Scholar
• PERRY G, MANT GK, MORRISON EL SACKS S, WOODCOOK J, WISER, IMBIMBO BP: Pharmacokinetics of rulloxacin In patients with impaired renal function. Antimicrob. Agents Chemother. (1993) 37:637–641.
   PubMedGoogle Scholar
• PETERSON LR, QUICK JN, JENSEN B, HOMANN S, JOHNSON S, TENQUIST J, SHANHOLTZER C, PETZEL RA, SINN L, GERDING DN: Emergence of ciprofloxacin resis-tance in nos000mial methicillin-resistant Staphylococ-cus aureus (MRSA) isolates during ciprofloxacin plus rifampin therapy for MESA colonization. Arch. Intern. Med. (1990) 150:2151-2155. A paper that illustrates the rapid emergence of clinical resistance to ciprofloxacin in staphylococci.
   Google Scholar
• PFALLER MA, BARRY AL, FUCHS PC: Antimicrobial activ- ity and disk diffusion susceptibility testing of Ro 40–6890, the active metabolite of the new cephalosporin ester, Ro 41–3399.
   Google Scholar
• Antimicrob. Agents Chemother. (1993) 37:893–895.
   Google Scholar
• PIDDOCK LjV, ZHU M: Mechanism of action of sparflox-acin against and mechanism of resistance in Gram-negative and Gram-positive bacteria. Antimicrob. Agents Chemother. (1991) 35:2423–2427.
   PubMed Web of Science ®Google Scholar
• POLAK A, HARTMAN PG: Antifungal chemotherapy- are we winning? In: Progress in Drug Research (1991) 37:181–269.
   PubMedGoogle Scholar
• Jucker E (Ed), Birkhauser Verlag, Basel.
   Google Scholar
• PRIVITERA G, et al.: Biliary excretion of rufloxacin in humans. Antimicrob. Agents Chemother. (1993) 37.2545–2549.
   PubMed Web of Science ®Google Scholar
• QADRI SMI-I, UENO Y, SALDIN H, CUNHA BA: In vitro activity of cefdinir (FK 482, PD 134393, CI-983): a new orally active cephalosporin. Chemotherapy (1993) 39:112–119.
   PubMed Web of Science ®Google Scholar
• RAOULT D, BRES P, DRANCOURT M, VESTA'S G: In vitro susceptibilities of Coxiella burnetii, Rickettsia rick-ettsii, and Rickettsia conori to the fluoroguinolone sparfloxacin. Antimicrob. Agents Chemother. (1991) 35:88–91.
   PubMed Web of Science ®Google Scholar
• RASTOGI N, LABROUSSE U, GOH KS, DESOUSA JPC: An-thnycobacterial spectrum of sparfloxacin and its activi-ties alone and in association with other drugs against Mycobacterium avium complex growing extracellu-lady and intracellularly in murine and human macro-phages. Antimicrob. Agents Chemother. (1991) 35:2473–2480.
   PubMed Web of Science ®Google Scholar
• RASTOGI N, GO1I KS: In vitro activity of the new difluor-inated guinokme sparfloxacin (AT-4140) against Myco-bacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin. Antimicrob. Agents Chemother. (1991) 35:1933–1936.
   PubMed Web of Science ®Google Scholar
• READING C, COLE M: Clavulanic acid: a beta-lactamase- inhibiting beta-lactarn from Streptomyces clavuligerus. Antimicrobial Agents and Chemotherapy (1977) 11:852–857.
   PubMed Web of Science ®Google Scholar
• Describes the first important inhibitor of 13-1actamase.
   Google Scholar
• REECE RJ, MAXWELL A: DNA gyrase - structure and function. Critical Reviews in Biochemistry and Molecular Biology (1991) 26(3-4):335–375.
   PubMed Web of Science ®Google Scholar
• REINER R, WEISS U, BROMBACHER U, LANZ P, MONTA-VON M, FLIRLENMEIER A, ANGEHERN P, PROBST PJ. Ro 13-9904/001, a novel potent long-acting parenteral cephalosporin. J Antibiotics (1980) 33:783–786.
   Google Scholar
• RENAUDIN H, BOUSSENS B, BEBEAR C: In vitro activity of RP 59500 against Mycoplanna. 31st International Conference On Antimicrobial Agents And Chemotherapy Chicago, (1991), Abstr. 897.
   Google Scholar
• RENAUDIN H, BEBEAR C: Activltkin vitro de la sparflox-acine sur les mycyplasmes. Patho. Biologie. (1992) 40:450–454.
   PubMedGoogle Scholar
• RICHARD P, GUTMANN L: Sparfloxacin and other new fluoroguinolones. J. Antimicrob. Chemother. (1992) 30:739-744. A review of the antimicrobial and pharrnacokinetic properties of sparfloxacin.
   Google Scholar
• RIGHTER J: Pneumococcal meningitis during intrave-nous ciprofloxacin therapy. Amer. J. Med. (1990) 88:548. •
   Google Scholar
• RIPA S, LA ROSA F, PRENNA M, GHIZZA A: Ceforanide: human pharmacokinetics after iv injection. Drugs Exptl. Clin. Res. (1982) 8:269–273.
   Google Scholar
• RODRIGUEZ-BARBERO J, MARINO EL, DOMINGUEZ-GIL A: Pharmacokinetics of cefmetazole administered intra-muscularly and intravenously to healthy adults. Antimi-crob. Agents Chemother. (1985) 28:544–547.
   PubMed Web of Science ®Google Scholar
• ROLIN O, BOUANCHAUD DH: It vivo efficacy of RP 59500, a new synergistic antibacterial agent, in Staphy- lococcus aureus and in Streptococcus pnetemoniae mouse experimental infections. 30th International Con-ference On Antimicrobial Agents And Chemotherapy, Atlanta, (1991), Abstr. 787.
   Google Scholar
• ROLINSON GN: fi-lactam antibiotics. J. Antimicrob. Chemother. (1986) 17:5–36.
   PubMed Web of Science ®Google Scholar
• ROUSE MS, TALLAN BM, STECKELBERG JM, HENRY NK, WILSON WR: Efficacy of cilofungin therapy adminis-tered by continuous intravenous infusion for experi-mental disseminated canditliasis in rabbits. Antimicrob. Agents Chemother. (1992) 36:56–58.
   PubMed Web of Science ®Google Scholar
• ROWIN GL, MILLER JE, ALBERS-SCHONBERG G, ONISHI JC, DAVIS D, DULANEY EL: Verlatnelin, a new antifungal agent J. Antibiot. (1986) 39:1772–1775.
   Google Scholar
• ROY K, MUKHOPADHYAY T, REDDY GCS, DESIKAN KR, • GANGULI BN: Mulundocandin, a new lipopeptide anti-biotic. L Taxonomy, fermentation; isolation and char-acterization. J. Antibiot. (1986) 40:275–280.
   Google Scholar
• RUIZ-HERRERA J: Biosynthesis of 13-glurans in fungL Antonie van Leewenhoek (1991) 60:73-81. A good review of glucan biosynthesis.
   Google Scholar
• SAITO A, TOMIZAWA M, NAKAYAMA I, SATO K: Basic and clinical studies on ref.-B.1in. Chemotherapy (Tokyo)(1992) 40:258–266.
   PubMedGoogle Scholar
• SAITO A: Influence of milk on the absorption of NM441, a new prodrug type of guinolone. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, (1993), Abstr. 1006.
   Google Scholar
• SAITO H, TOMIOKA H, SATO K: Comparative antimyco-bacterial activities of newly synthesized guinolones, AM-1155 and sparfloxacin. 32nd InConferenceon Antimicrobial Agents and Chemotherapy, Anaheim (1992) Abstr. 998.
   Google Scholar
• SAITO H, TOMIOKA H, SATO K: In vitro and in vivo antimycobacterial activities of a new guinokone, DU-6859a. 33rd Interscience Conference on Antimicrobiol Agents and Chemotherapy, New Orleans, (1993), Abstr. 80.
   Google Scholar
• SAKAGAMI K, ATSUMI K, TAMURA A, YOSHIDA T, NISHI-HATA K, FUKATSU S: Synthesis and oral activity of ME 1207, a new orally active cephalosporin. J. Antibiot. (1990) 43:1047–1050.
   PubMed Web of Science ®Google Scholar
• SAKAGAMI K, ATSUMI K, YAMAMOTO Y, TAMURA A, YOSHIDA T, NISHIHATA K, FUKATSU S: Synthesis and oral activity of pivaloyloxymethyl 74(Z)-2-(2-ami-nothiazol-4-y0-2-methoxylminoacetamidol-3(2)-(4-m ethylthiazol-5-yDvinyl-3-cephem-4-carboxylate (ME 1207) and its related compound. Chemical Pharmaceuti-cal Bulletin (1991) 39:2433–2436.
   PubMedGoogle Scholar
• SAKAGAMI K, IWAMATSU K, ATSUMI K, HATANAKA M: Synthetic cephalosporins VIII. Synthesis and antibacte-rial activity of CP6232, a new antipseudomonal cepha-losporin. J. Antibiot. (1992) 45:595–598.
   Google Scholar
• SAKAMOTO H, MINE Y, KAMIMURA T, HIROSE T, KUWA-HARA A: FK-518, a new parenteral antipseudomonal cephalosporin IV. Pharmacokinetics in experimental animals. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy Atlanta (1990) Abstr. 457.
   Google Scholar
• SAKANE K, KAWABATA K, INAMOTO Y, OKUDA S, KAMIMURA R, TAKAYA T: FK-518, a new parenteral anti-pseudomonal cephalosporin L Synthesis and structure-activity relationships of 3-aminopyra-zoliomethyl cephalospoins. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy Atlanta (1990) Abstr. 454.
   Google Scholar
• SAKANE K, KAWABATA K, INAMOTO Y, OKUDA S, KAMINIURA T, TAKAYA T. FK 518, a new parenteral antipseudomonal cephalosporin L Synthesis and struc-ture-activity relationships of 3-arainopyrazoliomethyl cephalosporin. 30th Intersci. Conf Antimicrob, Agent Chemother., Atlanta 1990 Abstr. 454.
   Google Scholar
• SALONEN J, NIKOSKELAINEN J: Lethal infections in pa-tients with hematological malignancies. Eur. J. Haema-tol. (1993) 51:102–108.
   PubMed Web of Science ®Google Scholar
• SANDERS CC, SANDERS WEJ: f3-lactam resistance in Gram-negative bacteria: global trends and clinical im- pact. Clinical Infectious Diseases (1992) 15:824-839.Excellent review of the impact of P-lactamases on cell-wall inhibitors.
   Google Scholar
• SANDRIN C, PEYPOUX F, MICHEL G: Coproduction of surfactin and iturin A, lipopeptides with surfactant and antifungal properties, byBaciihrs subtilis. Biotech. Appt Biochem. (1990) 12:370–375.
   PubMed Web of Science ®Google Scholar
• SANGUINETI A, C.ARMICHAEL JK, CAMPBELL K: Flucona-zole-resistant Candida albicans after long-term sup-pressive therapy. Archives of Internal Medicine (1993) 153:1122–1124.
   PubMed Web of Science ®Google Scholar
• SARAL R: Candida and Aspergilliss infections in imxnu-nocompromised patients - an overview. Rev. Infect. Dis. (1991) 13:487–492.
   PubMedGoogle Scholar
• SATO K, HOSHINO K, TANAKA M, HAYAKAWA I, OSADA Y: Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob. Agents Chemother. (1992) 36:1491–1498.
   PubMed Web of Science ®Google Scholar
• SATOH H, TSUJI T: 1-phosphocephalosporins - I - Syn- thesis of racemic 7-unsubstituted-1-phosphadethio-3-cephem- 1-oxides. Tetrahedron Lett (1984) 25: 1733-1736.
   Google Scholar
• SATOH M, TAKEUCHI H, YOSHIDA O: Prominent effects of a newer injectable cephalosporin, E1077 on the experimental refractory complicated UTI caused by E. faecalis and P. aeruginosa in rats. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 871.
   Google Scholar
• SATOI S, YAGI A, ASANO K, MIZUNO K, WATANABE T: Studies on aculeacin. IL Isolation and characterization of aculeacins B, C, D, E, F and G. J. Antibiot. (1977) 30:303–307.
   Google Scholar
• Describes the isolation and in vitro activity of the minor aculeacins. The structures of aculeacins B-G have not been fully determined.
   Google Scholar
• SAWISTOWSKA-SCHRODER ET, KERRIDGE D, PERRY H: Echinocandin inhibition of 1,3-13-D-glucan synthase from Candida albkans. FEBS Lett. (1984) 173:134–138.
   PubMed Web of Science ®Google Scholar
• SCHAAD UB: Role of the new quinolones in pediatric practice. Pediatr. Infect. Dis. J. (1992) 11:1043-1046. A thorough review surrounding the contentious issue of using fluoroquinolones in children. Data concerning the frequency of arthralgia and other side effects is presented and the currently accepted indications along with potential future indications in paediatrics are clearly outlined.
   Google Scholar
• SCHMATZ DM, ROMANCHECK MA, PITTARELLI LA, SCHWARTZ RE, ROMTLING RA NOLLSTADT KH, VANMID-DLESWOR'TH FL, WILSON KE, TURNER MJ: Treatment of Pneumocystis carinii pneumonia with 1,3-13-glucart synthesis inhibitors. Proc. NatI Acad. Sci. USA (1990) 87:5950–5954.
   PubMed Web of Science ®Google Scholar
• First account of the use of a 13-(1,3)-glucan synthesis inhibitor as an effective treatment for experimental P. carinii pneumonia.
   Google Scholar
• SCHMATZ DM, POWLES MA, MCFADDEN DC, PITTARELLI L, BALKOVEC J, HAMMOND M, ZAMBIAS R, LIBERATOR P, ANDERSON J: Antipneumocystis activity of water-sol-uble lipopeptide L-693,989 in rats. Antimicrob. Agents Chemother. (1992) 36:1964–1970.
   PubMed Web of Science ®Google Scholar
• Full account of the activity of L-693,989 in rat PCP model.
   Google Scholar
• SCHMATZ DM, ABRUZZO G, POWLES MA, MCFADDEN DC, BALKOVEC JM, BLACK RM, NOLLSTADT K, BARTIZAL K: Pneumocartdins from Zalerion arboricola IV. Biologi-cal evaluation of natural and semisynthetic pneumo-candins for activity against Pneumocystis carinii and Candida species. J. Antibiot. (1992) 45:1886–1891.
   Google Scholar
• SAR and biological efficacies of the pneumocandins and deoxygen-ated derivatives. A diverging SAR for Candida and P. carinii is noted.
   Google Scholar
• SCHMATZ DM, POWLES M, MCFADDEN DC, VADAS E, MEISNER D, HAJDU R: Treatment and prevention of P.carinii pneumonia in the rat using aerosolized water soluble lipopeptide L-693,989. Program and Abstracts of the 31st lnterscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, 1991 Abstr, 208. Efficacy and prophylaxis with L-693089 by aerosol delivery in a rat PCP model.
   Google Scholar
• SCHMATZ DM, MCFADDEN DC, LIBERATOR P, ANDERSON J, POWLES MA: Evaluation of new semisynthetic pneu-mocandins against Pneumocystis carinii in the immu-nocompromised rat. Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Che-motherapy, New Orleans, Louisiana, 1993 Abstr. 356. L-733,560 was effective (ED9o) at O.01 mg/kg in a rat PCP model.
   Google Scholar
• SCHMATZ DM: The use of 13–1,3-glucan synthesis inhibi- tors for the treatment and prevention of Pneumocystiscarinii pneumonia. In: Pneumocystis carinii (1994). Walzer PD (Ed), Marcel Dekker, New York. A good review with a brief history of 3-(1,3)-glucan synthesis inhibitors, mechanism of action and use as anti-Pneumocystisagents.
   Google Scholar
• SCHROGIE JJ, DAVIES RO, YEH KC, ROGERS P, HOLMES GI, SKEGGS H, MARTIN CM: Bioavallability and pharma-cokinetics of cefoydtin sodium. J. Antimicrob. Chemother. (1978) 4 (Suppl B):69–78.
   Google Scholar
• SCHWARTZ RE, MASUREKAR P, WHITE R: Discovery, production process development, and isolation of prteumocandin Bo. In: Cutaneous Antifungal Agents(1993). Rippon JW, Fromtling RA (Eds), Marcel Dekker, New York. Full account of the discovery of pneumocandin Bo
   Google Scholar
• SCHWARTZ RE, GIACOBBE RA, BLAND JA, MONAGHAN RL: L-671,329, a new antifungal agent L Fermentation and isolation. I Antibiot. (1989) 42:163–167.
   Google Scholar
• First pneumocandin to be isolated.
   Google Scholar
• SCHWARTZ RE, SESIN DF, JOSHUA H, WILSON KE, KEMPF AJ, GOKLEN KA, KUEHNER D, GAILLIOT P, GLEASON C, WHITE R, INAMINE E, BILLS G, SALMON P, ZITANO L: Pneumocandins from Zalerion arboricola L Discovery and isolation. J. Antibiot. (1992) 45:1853–1866.
   PubMed Web of Science ®Google Scholar
• Isolation of pneumocandin Bo.
   Google Scholar
• SCRIVER SR, 'TYRRELL G, WILLEY BM, KREISWIRTH BN, LOW DE: In vitro assessment of RP 59500 (RP) against vancomycin-resistant enterococci. 33rd International Conference On Antimicrobial Agents And Chemotherapy New Orleans, (1993), Abstr. 1057.
   Google Scholar
• SEGRE G, CERRETANI D, URSO R: Pharmacolcinetics of rufloxacin in healthy volunteers. Eur.J. Clin. Pharmacol. (1992) 42:101–105.
   PubMed Web of Science ®Google Scholar
• SEKINE Y, MATSUNAGA Y, MIYAZAKI H, et al.: Absorp-tion, distribution, metabolism and excretion of AT–4140 474 in animals. 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, (1988), Abstr. 1489.
   Google Scholar
• SESNLE J, DESATY T, DEVER J, JOANNIDES E, SHAPIRO M, VANDERROEST S: In vivo efficacy of a novel fluoroqui-nolone P1)140248. 33rd Interscience Conference on Antimi-crobial Agents and Chemotherapy, New Orleans, (1993), Abstr. 1020.
   Google Scholar
• SHAPIRO MA, DEVERIAJOANNIDES ET, SESNIE JC:In vivo activity of PD138312, a new F-naphthyridine with ex-cellent Gram-positive potency. 33rd Interscience Confer-ence on Antimicrobial Agents and Chemotherapy, New Orleans, (1993), Abstr. 1021.
   Google Scholar
• SHARMA NK, ANTEUNIS MJO: Benzylation of virginiamy-cin Si. Bull. Soc. Cbim. Belges (1988) 97:365–369.
   Google Scholar
• SHARMA NK, ANTEUNIS MJO: A search for phenolic protection in virginiamycin S. Bull. Soc. Chim. Belges (1989) 98:463–479.
   Google Scholar
• SHARMA SD, MEHRA U: Studies on fused 13-lactams: synthesis of novel 1-aza-analogs of cepham. Tetrahedron Lett (1984) 25: 1849-1852.
   Google Scholar
• SHEARER MJ, BECHTOLD H, ANDRASSY K, KODERISCH J, MCCARTLY PT, TREUK D, JAHNCHEN E, RITZ E: Mecha-nism of cephalosporin-induced hypoprothrom-binemia: relation to cephalosporin side chain, vitamin K metabolism and vitamin K status. J. Clin. Pharmacol. (1988) 28:88–95.
   PubMed Web of Science ®Google Scholar
• SHEPHERD MG, GOPAL PK: Candkia albicans: Cell wall physiology and metabolism. In: Candida and Candi-damycosis (1991). Tumbay E (Ed), Plenum Press, New York.
   Google Scholar
• SHIBA K, YOSHIDA M, UZU M, MATSUBARA S, SAKAI O: Effect of antacids on oral absorption of a new 8-methoxy fluoroquinolone, Q-35. 33rd Interscience Con-ference on Antimicrobial Agents and Chemotherapy, New Orleans, (1993) Abstr. 1505.
   Google Scholar
• SHIBA K, YOSHIDA M, HORI S, SHIMADAL SAITO A, SAKAI O: Pharraacokinetic interaction of OPC-17116 with probenecid in healthy volunteers. 31st Interscience Con-ference on Antimicrobial Agents and Chemotherapy, Atlanta, (1991), Abstr. 1483.
   Google Scholar
• SHIBA K, MAEZAWA H, YOSIIIDA M: Comparative clinical study of cefditoren pivoxil and cefteram pivoxil for bacterial pneumonia by a double-blind method. Chemo-therapy (Tokoyo) (1992) 40:1472.
   Google Scholar
• SHIBAHARA S, OKONOGI T, YOSHIDA T, MURAI Y, KUDO T, INOUYE S, KONDO S: A new aminothiazolylcepha-losporin having 1-carboxyethoxyimino group, ME1228. J. Antibiot. (1990) 43:62–69.
   PubMedGoogle Scholar
• SHIBAHARA S, OKONOGI T, MURAI Y, INOUYE S, CHRIS-TENSEN BG: Structure-activity relationships of 2f1-inethyloxacephalosporin. 29th Intersci. Conf Antimicrob. Agent Chemother. Houston 1989 Abstr. 358.
   Google Scholar
• SHIBARA S, OKONOGI T, MURAI Y, KUDO K, YOSHIDA T, KONDO S, CHRISTENSEN BG: Synthesis of a novel 20-methy1-1-oxacephlaosporin OCP-9-176. J. Antibiotics (1988) 41:1154–1157.
   PubMedGoogle Scholar
• SHIMIZU K, SAITO A, YAMAMATO S: Carnitine status and safety of S-1108, a new oral cephena, in patients. 32nd Interscience Conference on Antimicrobial Agents and Che-motherapy Anaheim (1992) Abstr. 185.
   Google Scholar
• SHIMIZU K, SAITO. A, SHIMADA J: Carnitine status and safety after administration of S-1108, a new oral cephera, to patients. Antimicrob. Agents Chemother (1993) 37:1043–1049.
   PubMed Web of Science ®Google Scholar
• SILLEY P, GRIFFITHS JW, MONSEY D, HARRIS AM: Mode of action of GR69153, a novel catechol-substituted cephalosporin, and its interaction with the tonB-de-pendent iron transport system. Antimicrob. Agents Chemother. (1990) 34:1806–1808.
   PubMed Web of Science ®Google Scholar
• SILVER LL, BOSTIAN KA: Discovery and development of new antibiotics: The problem of antibiotic resistance. Antimicrobial Agents and Chemotherapy (1993) 37(3):377–383.
   PubMed Web of Science ®Google Scholar
• SINGH M, CHAUDRY MA, YADAVA JN, SANYAL SC: The spectrum of antibiotic resistance in human and veteri-nary isolates of Escitericbia colt collected from 1984-1986 in northern India. Journal of Antimicrobial Chemo-therapy (1992) 29:159–168.
   PubMed Web of Science ®Google Scholar
• SMITH BR, LE FROCK JL, THYRUM PT, DORET BA, YEH C, ONESTE G, SCHWARTZ A, ZIMMERMAN JJ: Cefotetan pharmaeoldnetics in volunteers with various degrees of renal function. Antimicrob. Agents Chemother. (1986) 29:887–893.
   PubMed Web of Science ®Google Scholar
• SMULIAN AG, WALZER PD: The biology ofPneumocystis carinii. Crit Rev. Micro biol. (1992) 18:191–216.
   PubMed Web of Science ®Google Scholar
• An updated review of the biology of P. carinii.
   Google Scholar
• SMYTH RD, PFEFFER M, GLICK A, VAN HARKEN DR, HOTTENDORF GH: Clinical pharmacokinetics and safety of high doses of ceforanide (BLS 786) and cefa-zolin. Antimicrob. Agents Chemother. (1979) 16:615–621.
   PubMed Web of Science ®Google Scholar
• SORGEL F, KINZIG M: Pharmacokinetics of gyrase inhibi-tors, part 2: renal and hepatic elimination pathways and drug interactions. Amer. J. Med. (1993) 94 (Suppl. 3A):56S-69S. An excellent review covering the metabolism of fluoroquinolones in humans.
   Google Scholar
• SOUSSY CJ, ACAR JF, CLUZEL R, COURVALIN P, DUVAL J, FLEURETTE J, MEGRAUD, MEYRAN M, THABAUT A: A collaborative study of theft* vitro sensitivity to RP 59500 of bacteria isolated in seven hospitals in France. J. Antimicrob. Chemother. (1992) 30(Suppl. A):53–58.
   Google Scholar
• SPANGLER SK, JACOBS MR, APPELBAUM PC: Susceptibili-ties of penicillin-susceptible and -resistant strains of Streptococcus pneutnoniae to BP59500, vancomydn, erythromydn, P1)131628, sparfloxacin, temafloxacin, WIN57273, ofloxacin, and ciprofloxacin. Antimicrob. Agents Chemother. (1992) 36:856–859.
   PubMed Web of Science ®Google Scholar
• SPANGLER SK, JACOBS MR, PANKUCH GA, APPELBAUM PC: Susceptibility of 170 penicillin-susceptible and peni-cillin-resistant pneumococci to six oral cephalospor-ins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.J. Antimicrob. Chemother. (1993) 31:273–280.
   PubMed Web of Science ®Google Scholar
• SPENCER RC. Catecholic13-lactams: facilitated transport. J. Antimicrobial Chemother. (1990) 26:733–737.
   PubMed Web of Science ®Google Scholar
• SREEDHARAN S, ORAM M, JENSEN B, PETERSON Lit, FISHER LM: DNA gyrase gyrA mutations in ciprofkm-acin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance in Escherichia coil. J. Bacteriol. (1990) 172:7260-7262. A detailed study of mutations in DNA gyrase at the genetic level.
   Google Scholar
• SREEDHARAN S, PETERSON LR, FISHER LM: Ciprofloxacin resistance in coagulase-positive and -negative staphylo-cocci; role of mutations of serine 84 in the DNA gyrase A protein ofStapbylococcus aureus andS. epidermidis Antimicrob. Agents Chemother. (1991) 35:2151–2154.
   PubMed Web of Science ®Google Scholar
• STOCK JB, NINFA AJ, STOCK AM: Protein phosphoryla- don and regulation of adaptive responses in bacteria. Microbiological Reviews (1989) 53:450–490.
   PubMedGoogle Scholar
• SUNDELOF JG, HAJDU R, CLEARE WJ, ONISHI J, KROPP H: Pharmacokinetics of L-671,329 in rhesus monkeys andDBA/2 mice. Antimicrob. Agents Chemother. (1992) 36:607–610.
   PubMed Web of Science ®Google Scholar
• Pharmacokinetic comparison of pneumocandin Ao (L-671,329) and cilofungin in rhesus monkeys and mice.
   Google Scholar
• SZABO I, BARABAS J, TAR A, KISS L, FILEP M, SCHMIDT T, MAROSSY K, TOTH-MARTINEZ B, BARABAS G, HERNADI F: In vitro investigation of BK-218, a new oral and parenteral cephalosporin. Antimicrob. Agents Chem other. (1990) 34:349–354.
   PubMed Web of Science ®Google Scholar
• TAFT CS, SELITRENNIKOFF CP: Cilofungin inhibition of (1,3)-P-glucan synthase: The lipophilic side chain is essential for inhibition of enzyme activity. J. Antibiot. (1990) 43:433–437.
   PubMed Web of Science ®Google Scholar
• TAFT CS, STARK T, SELITRENNIKOFF CP: Cilofungin (LT121019) inhibits Candida albicans (1,3)43-D-glucan synthase activity, Antimicrob. Agents Chemother. (1988) 32:1901–1903.
   PubMed Web of Science ®Google Scholar
• TAIRA K, KOGA H, KOHNO S: Accumulation of a newly developed fluoroquinolone, OPC-17116, by human po-lymorphonuclear leukocytes. Antimicrob. Agents Chemother. (1993) 37:1877–1881.
   PubMed Web of Science ®Google Scholar
• TAKAGI, K YAMAKI K, NADAI M, KUZUYA T, HASEGAWA T: Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic pa-tients. Antimicrob. Agents Chemother. (1991) 35:1137–1141.
   PubMed Web of Science ®Google Scholar
• TAKASHMA I, NGOMA M, HASHIMOTO N: Antimicrobial effects of a new carboxyquinolone drug, Q-35, on five serogroups of Leptospira interrogans. Antimicrob. Agents Chemother. (1993) 37:901–902.
   PubMed Web of Science ®Google Scholar
• TAKESAKO K, IKAI K, HARUNA F, ENDO M, SHIMANAKA K, SONO E, NAKAMURA T, KATO I, YAMAGUCHI H: Aureobasidins, new antifungal antibiotics taxonomy, fermentation, isolation, and properties. J. Antibiot. (1991) 44:919–924.
   PubMed Web of Science ®Google Scholar
• Isolation and in vitro activity of aureobasidins A-R.
   Google Scholar
• TAKESAKO K, KURODA H, INOUE T, HARUNA F, YOSHIKAWA Y, KATO I, UCHIDA K, HIRATAM T, YAMA-GUCHI H: Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic. J. Antibiot. (1993) 46:1414–1420.
   PubMed Web of Science ®Google Scholar
• Describes extensive in vitro and in vivo activity of aureobasidin A. Kill curves and acute toxicity is reported.
   Google Scholar
• TAKESHIMA H, INOKOSHI J, TAKEDA Y, TANAKA H, OMURA S: A deacylation enzyme for aculeacin A, a neutral lipophilic antibiotic, fromActinoplanes uta hen-sis: purification and characterization. J. Biochem. (1989) 105:606–610.
   PubMed Web of Science ®Google Scholar
• TAKUMA K, AIKAWA N, SHINOZAWA Y, HORI S, SASAKI J, HACHIYA S, SATOH M: Mechanism of elevated levels of E1077, a new cephalosporin, in burned rat eschar. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 870.
   Google Scholar
• TAMURA A, OKAMOTO R, YOSHIDA T, YAMAMOTO H, KONDO S, INOLTYE M, MITSUHASHI S: In vitro and in vivo antibacterial activities of ME-1207, a new cepha-losporin. Antimicrob. Agents Chemother. (1988) 32:1421–1426.
   PubMed Web of Science ®Google Scholar
• TANAKA K-I, et al.: Laboratory and clinical studies on levofloxacin. Jap.J. Antibiot. (1992) 45:548–556.
   Google Scholar
• TANAKA M, AOKI H, KURATA T, OKAZAKI O, HAKUSUI H: DU-6859a, a novel quinolone: pharmacokinetics in rats, dogs, and monkeys. 33rd Interscience Conference on An-timicrobial Agents and Chemotherapy, New Orleans, (1993), Abstr. 1000.
   Google Scholar
• TANG J, PARR TR: W-1 Solubilization and kinetics of Inhibition by cilofungin of Candida albicans (1,3)-0-D-glucan synthase. Antimicrob. Agents Chemother. (1991) 35:99–103.
   PubMed Web of Science ®Google Scholar
• The first solubilization of the Candida glucan synthase enzyme.
   Google Scholar
• TANG J, PARR TR, TURNER W, DEBONO M, LAGRANDUER L, BURKHARDT F, RODRIGUEZ M, ZWEIFEL M, NISSEN J, CLINGERMAN K: LY303366: A noncompetitive inhibitor of (1,3)-P-D-glucan synthases from Candida albicans and Aspergilius funtigatus. Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993 Abstr. 367. Poster showing noncompetitive inhibition of LY303366. The Ki (µM) was O.7 and O.11 for C. albicans and A. fumigatus.
   Google Scholar
• TASHIRO M, MAGOME E, MIKI S, SAKAGAMI K: Inclusion complex of a new orally active cephalosporin ME-1207 with fl-cyclodextrin. Chem. Pbarm. Bull. (1992) 40:1623–1625.
   Web of Science ®Google Scholar
• TENG R, KHOSLA NB, RENOLTF DN, GIRARD D, SILBER BM, FOULDS G, LISTON TE: Pharmacokinetics of CP-99,219, a new oral quinolone antibiotic, in Sprague-Dawley rats, beagle dogs and cynomolgus monkeys. Pharm. Res. (1993) 10:S336.
   Google Scholar
• TENG R, HARRIS SC, NIX D, SCHENTAG J, FOULDS G, SILBER BM, LISTON TE: Pharmacokinetics of CP-99,219, a new quinolone antibiotic, following single oral doses to healthy volunteers. 33rd Interscience Conference An-timicrobial Agents and Chemotherapy, New Orleans, (1993), Abstr. 1512.
   Google Scholar
• TERNANSKY RJ, DRAHEIM SE, PIKE AJ, BELL FW, WEST SJ, JORDAN CL, WI) CYE, PRESTON DA, ALBORN W, RASHER JS et al.: Discovery and structure-activity relationship of a series of 1-carba-l-dethiacephems exhibiting activity against methicillin-resistant Staphylococcus aureus. J. Med. Chem. (1993) 36:1971–1976.
   Google Scholar
• THOMSON KS, SANDERS CC, HAYDEN ME:In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises. Antimicrob. Agents Chemother. (1991) 35:2329-2334. A careful analysis describing the activity of clinafloxacin against ciprofloxacin-resistant staphylococci. Includes frequencies of in vitro resistance emergence.
   Google Scholar
• TKACZ JS: Glucan biosynthesis in fungi and its inhibi-tion. In: Emerging Targets In Antibacterial And Antifungal Chemotherapy (1992). Sutcliffe J, Georgopapadakou NH (Eds), Chapman and Hall, New York. A good review of glucan biosynthesis and antifungal agents inhibit-ing this target.
   Google Scholar
• TOMIOKA H, SAITO H, SATO K: Comparative antimyco- bacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob. Agents Chemother. (1993) 37:1259–1263.
   PubMed Web of Science ®Google Scholar
• TOTSUKA K, SHIMIZU K: Pharmacokinetics of NM441, with probenecid in healthy volunteers. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, (1993), Abstr. 1005.
   Google Scholar
• TRABER R, KELLER-JUSLEN C, LOOSLI H-R, KUHN M, WAR-TBURG A: Cyclopeptid-antibiotika aus AspergUlus-arten. Struktur der echinocandine C und D. Hely. Chim. Ada (1979) 62:1252–1267.
   Google Scholar
• This paper gives a full account of the isolation, and structure determination of echinocandins B, C and D.
   Google Scholar
• TSUJI T, SATO H, NARASIDA M, HAMASHIMA Y, YOSHIDA T: Synthesis and antibacterial activty of 6315 S, a new member of oxacephem antibiotics. J. Antibiotics (1985) 38:466–478.
   PubMed Web of Science ®Google Scholar
• TSUSHIMA M, TAMURA A, HARA T, IWAMATSU K, SHIBA-HARA S: Synthesis and biological properties of CP0467, a new cephem possessing excellent activity against MESA. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy Anaheim (1992) Abstr. 394.
   Google Scholar
• TURCO' IL A, BERGERON MG: Pharmacodynamic inter-action between RP 59500 and Gram-positive bacteria Infecting fibrin clots. Antimicrob. Agents Chemother. (1992) 36(10):2211–2215
   PubMed Web of Science ®Google Scholar
• TURNER W, DEBONO M, LAGRANDEUR L, BURKHARDT F, RODRIQUEZ M, ZWEIFEL M, NISSEN J, CLINGERMAN K, GORDEE R, ZEC1CNER D, PARR T, TANG J: LY303366- A new semi-synthetic lipopeptide antifungal agent related to echinocandin B.- 2. Rigid, polyaromatic sidechains pro-viding oral activity. Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Che-motherapy, New Orleans, Louisiana, 1993 Abstr. 358. SAR describing the Lilly side chain echinocandin analogues.
   Google Scholar
• UCHIDA K, MATSUBARA T, HIRAUCHI K: Studies on oxacephem antibiotics: comparison of the effects of oxa-1 and 1-thia cephalosporins on blood coagulation activities and vitamin K metabolism in rats. Jap J. Phar-macol (1989) 50:283–288.
   PubMed Web of Science ®Google Scholar
• UENO K, KATO H, WATANABE K, BANDOH K, TANAICA Y, KATO N: Effect of AM-1155 oral administration on fecal microflora of humans. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, (1991), Abstr. 1004.
   Google Scholar
• UNE T, FUJIMOTO T, SATO K, OSADA Y: In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob. Agents Chemother. (1988) 32:1336–1340.
   PubMed Web of Science ®Google Scholar
• VANDERWOUDE MW, BRAATEN BA, LOW DA: Evidence for global regulatory control of pilus expression in Escbericbia colt by Lip and DNA methylation - Model building based on analysis of PAP. Mol Microbiol (1992) 6(17):2429–2435.
   PubMed Web of Science ®Google Scholar
• VANNUFFEL P, DI GAMBAITISTA, M COCITO C: The role of RNA bases in the interaction of peptidyltransferase Inhibitors with bacterial ribosomes. J. Biol. Chem. (1992) 267:16114–16120.
   PubMed Web of Science ®Google Scholar
• VAZQUEZ D: The streptogramin family of antibiotics. In: Antibiotics. (1975) Corcoran JN, Hahn FE (Eds), Springer, Berlin, Heidelberg, New-York, V01111:521–534.
   Google Scholar
• The first review on streptogramins.
   Google Scholar
• VERBIST L, VERHAEGEN J: Comparative in vitro activity of RP 59500. J. Antimicrob. Chemother. (1992) 30(Suppl.A):39–44.
   Google Scholar
• VIDEAU D: Etude de l'activité bactericide de la pristi- namycine Path.IA Biol. (1982) 30:529–534.
   Google Scholar
• WAITES KB, DUFFY LB, SCHMID T, CRABB D, PATE MS, CASSELL GH: In vitro susceptibilities of Mycoplasmapneumoniae,M. botninis, and Ureaplasma urealyticum to sparfloxacin and PD127391. Antimicrob. Agents Chemother. (1991) 35:1181–1185.
   Google Scholar
• WAKABAYASHI E, MITSUHASHI S: Antibacterial activities of AM-1155 and AM-1174, novel 6-fluoro-8-methoxy quinolones. 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, (1991), Abstr. 1493.
   Google Scholar
• WAKEBE H, MITSUHASHI S: Comparative in vitro activi-ties of a new quinolone, OPC-17116, possessing potent activity against Gram-positive bacteria. Antimicrob. Agents Chemother. (1992) 36:2185–2191.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, JAROSINSKI PF, FROMTLING RA: Increasing usage of systemic antifungal agents. Diagn. Microbiol. Infect. Dis. (1990) 13:37–40.
   PubMed Web of Science ®Google Scholar
• WALSH TJ, LEE JW, KELLY P, BACHER J, LECCIONES J, THOMAS V, LYMAN C, COLEMAN D, GORDEE R, PIZZO PA: Antifuuagal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-f3-glucan synthetase inhibitor, dur-ing continuous and intermittent intravenous infusions In treatment of experimental disseminated candidiasis. Antimicrob. Agents Chemother. (1991) 35:1321–1328.
   PubMed Web of Science ®Google Scholar
• Cilofungin displays non-linear saturable plasma pharmacokinetics. Doubling of dosage produced tissue levels ten-fold higher with an antibiotic effect 102 to 104 greater.
   Google Scholar
• WANG Q, CALVO JM: LRP, a global regulatory protein of Escbericbia coil, binds co-operatively to multiple sites and activates transcription of IlvIH. J Mol Biol (1993) 229(2):306–318.
   PubMedGoogle Scholar
• WATANABE N, INOUE E, KATSU K, IYOBE S, MITSUHASHI S. In vitro activity of E-1040 against imipenem-resistant Pseudomonas aeruginosa strains. J. Antimicrob. Chemother. (1992) 36:684–686.
   Google Scholar
• WATANABE NA, HIRUMA R, KATSU K: Comparative in vitro activities of newer cephalosporins cefclidin, ce-fepime and cefpirome against ceftazidime or itnipenem-resistant Pseudomonas aeruginosa. J. An-timicrob. Chemother. (1992) 30:633–641.
   PubMed Web of Science ®Google Scholar
• WATANABE NA, NAGASU T, KATSU K, KITOH K: E-0702, a new cephalosporin, is incorporated into Escbericbia colt cells via the tonB dependent iron transport system. Antimicrob. Agents Chemother. (1987) 31:497–504.
   PubMed Web of Science ®Google Scholar
• WATANABE NA, HIRUMA R, KATSU K. In vitro evaluation of E-1077, a new cephalos porin with broad antibacterial spectrum. Antimicrob. Agents Chemother. (1992) 36:589–597.
   Google Scholar
• WATANABE Y, GONDA A, KIDOKORO T: Penetration of ceibuperazone, a new cephamycin antibiotic into hu-man peritoneal exsudate.Jap.J. Antibiotics (1984) 37:261–266.
   PubMedGoogle Scholar
• WEAVER SS, LEBLANC BM, BODEY GP: BLS 786 (cefora-nide), anew parenteral cephalosporin in in vitro stud-ies. Antimicrob. Agents Chemother. (1979) 15:318–322.
   PubMedGoogle Scholar
• WEISSBERGER B, ABRUZZO GK, FROMTLING RA, VALIANT ME, SHUNGU DL, GRADEBUSH HH: L-656575 (OPC-9-176): a novel oxacephem. In vitro activity against aero-bic and anaerobic clinical isolates. J. Antibiotics (1988) 41:1130–1136.
   Google Scholar
• WEN-CHIF1 L, SEINER V, DEAN LD, TREJO WH, PRINCIPE PA, MEYERS E, SYKES RB: Production of vernamycin by aMicromonospora. J. Antibiotics (1981) 34(11):1515–1516.
   PubMed Web of Science ®Google Scholar
• WHITE RE, DEMUTH TP JR, BERK JD, TIETJEN RA, JAMI-ESON LA, KRAFT WG, MCOSKER CC, DAVIS BW, ROLTRKE FJ: Preparation and comparative antibacterial activity of quinolyl-cephem amines and carbamates. 33rd Inter-science Conference on Antimicrobial Agents and Chemother-apy New Orleans (1993) Abstr. 1491.
   Google Scholar
• WICHMANN CF, LIESCH JM, SCHWARTZ RE: L-671,329, a new antifungal agent U. Structure determination. J. Antibiot. (1989) 42:168–173.
   PubMed Web of Science ®Google Scholar
• WILLIAMS JD: Classification of cephalosporins. Drugs (1987) 34 (Suppl 2):15–22.
   PubMedGoogle Scholar
• WINGARD JR, MERZ WG, RINALDI MG, MILLER CB, KARP JE, SARAL R: Association of Torulopsis-glabrata infec-tions with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. (1993) 37:1847–1849.
   PubMed Web of Science ®Google Scholar
• WISE R, ANDREWS JM, MATTHEWS R, WOLSTENHOLME M: The in vitro activity of two new quinolones: rufloxacin and MF961. J. Antimicrob. Chemother. (1992) 29:649–660.
   PubMed Web of Science ®Google Scholar
• WISE R, JOHNSON J, O'SULLIVAN N, ANDREWS JM, IM-BIMBO BP: Pharmacokinetics and tissue penetration of rufioxacin, a long acting quinolone antimicrobial agent J. Antimicrob. Chemother. (1991) 28:905–909.
   Web of Science ®Google Scholar
• WISER, ANDREWS JM, BRENWALD N: The in vitro activity seof OPC-17116, a new 5-methyl substituted quinolone. J.Antimicrob. Chemother. (1993) 31:497–504.
   PubMed Web of Science ®Google Scholar
• WISE R, ANDREWS JM, ASHBY JP, THORNBEN D: Ceftib-uten - in vitro activity against respiratory pathogens, O-lactamase stability and mechanism of action. J. An-timicrobial Chemother. (1990) 26:209–213.
   PubMed Web of Science ®Google Scholar
• WISE R: unpublished data.
   Google Scholar
• WODDS JS, BUENNING MK, HANASONO GK: Latamoxef-associated hypoprothrobinaemia. Lancet ii(1983):408
   PubMed Web of Science ®Google Scholar
• WOLFSON JS, HOOPER DC: Bacterial resistance to qui-nolones: mechanisms and clinical importance. Reviews in Infectious Diseases (1989) 11:8960–8968.
   Google Scholar
• WV CYE, FLOKOWITSCH JE, ALBORN WEJ, TERNANSKY RJ, PRESTON DA: Mechanism of action of a series of 3-substituted-1-carbacephems against methicftlin-resis-tant Staphylococcus aureus (MRSA). 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans (1993) Abstr. 111.
   Google Scholar
• WV JF, CHIN NX, NEU HC: In vitro activity of a new fluoroquinolone, T-3761. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, (1993), Abstr. 1010.
   Google Scholar
• WOST J, HARDEGGER U: Comparative in vitro activity of Ro 40-6890, Ro 41-3399 and other antimicrobial agents against anaerobic bacteria. Eur. J. Clin. Microbiol. Infect. Dis. (1992) 11:946–949.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI H, HIRITANI T, IWATA K, YAMAMOTO Y: Studies on the mechanism of action of aculeacin A. J. Antibiot. (1982) 35:210–219.
   PubMed Web of Science ®Google Scholar
• YAMANAKA Y, YAMAMOTO T, EGASHIRA T: Effects of cephem antibiotics on rat liver aldehyde dehydro-genases. Jap. J. Pharmacol. (1983) 33:717–723.
   PubMedGoogle Scholar
• YASUNAGA M, YAMADAD II, YOSHIDA T, UCHIDA K: Pharmacokinetics and safety of 6315 S in normal vol-unteers. 24th Intersci. Conf Antimicrob. Agent Chemother. 1984 Washington.
   Google Scholar
• YAWADA Y, KANIMOTO Y, SAITO I: Pharmacokinetics of OPC-17116, a new quinolone, in patients with impaired renal function. 33rd Interscience Conference on Antimicro- bial Agents and Chemotherapy, New Orleans, (1993), Abstr. 409.
   Google Scholar
• YOKOTA T, TATEDA E, HIRAMATSU K: A novel quinolone useful orally and parenterally, T-3761: its in vitro an-tibacterial activity and cytotoxicity. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, (1993), Abstr. 1011.
   Google Scholar
• YOSHIDA H, KOJIMA T, YAMAGISHI J-I, NAKAMURA S: Quinolone resistance mutations of the gyrA gene of Escherichia coli. Molecular and General Genetics (1988) 211:1–7.
   PubMedGoogle Scholar
• YOSHIDA T, MITSUHASHI S: Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone. Antimicrob. Agents Chemother. (1993) 37:793–800.
   PubMed Web of Science ®Google Scholar
• YOSHIDA T, HAMASHIMA Y, KOMATSU Y, NOMURA K: S-1108, new oral cephem: antibacterial activity. 29th Interscience Conference on Antimicrobial Agents and Che-motherapy Houston (1989) Abstr. 368.
   Google Scholar
• YOSHIKAWA Y, IKAI K, UMEDA Y, OGAWA A, TAKESAKO K, KATO I: Isolations, structures, and antifungal activi- ties of new aureobasitlins. J. Antibiot. (1993) 46:1347–1354.
   PubMed Web of Science ®Google Scholar
• The structures and antifungal activities of aureobasidins Si, Sza, S2b, 53 and S4 are disclosed.
   Google Scholar
• ZAMB1AS RA, HAMMOND ML, HECK JV, BARTIZAL K, TRAINOR C, ABRUZZO G, SCHMATZ DM, NOLLSTADT KM: Preparation and structure-activity relationships of sim-plified analogues of the antifungal agent cilofungin: A total synthesis approach. J. Med. Chem. (1992) 35:2843–2855.
   PubMed Web of Science ®Google Scholar
• Paper describes a series of increasingly complex analogues of cilofungin with glucan synthase and antifungal activities monitored along the way. Demonstrates the importance of the homotyrosine moiety vis-a-vis tyrosine and the 3-hydroxy-4-methylproline residue. First approach to utilize solid-phase peptide synthesis in the con-struction of the linear peptide and lipophilic side chain.
   Google Scholar
• ZECKNER D, BUTLER T, BOYLAN C, BOYLL B, UN Y, RAAB P, SCHMIDTKE J, CURRENT W: LY303366, activity in a murine systemic candidiasis model. Program and Ab-stracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993 Abstr. 365. EDsos for LY303366 against systemic candidiasis were 0.3 mg/kg fp and 7.8 mg/kg po.
   Google Scholar
• ZECKNER D, BUTLER T, BOYLAN C, BOYLL B, UN Y, RAAB P, SCHMIDTKE J, CURRENT W: LY303366, activity againstsystemic aspergillosis and histoplasmosis in murine models. Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993 Abstr. 364. EDso for LY303366 against systemic aspergillosis was 19.6 mg/kg ip, but was inactive orally up to 50 mg/kg.
   Google Scholar
• ZECKNER D, BUTLER T, BOYLAN C, RAAB P, THOMAS L, FARMER J, GORDEE R, SCHMIDTKE J: LY295337 a noveldepsipeptide antifungal antibiotic. IL In vivo antifungal activity. Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, 1992, Abstr. 497.
   Google Scholar
• ZIMMERMAN J, COHEN A, THYRUM PT: Absolute bioavail- ability and compartmental analysis of intravenous and Intramuscular cefotetan in normal volunteers. J. Clin. Pharmacol. (1989) 29:151–157.
   PubMed Web of Science ®Google Scholar
• ZORNES L, STRATFORD R, NOVILLA M, TURNER D, BOY-LAN C, BOYLL B, BUTLER T, UN Y, ZECKNER D, TURNER W, CURRENT W: Single dose iv and oral administration pharmacokinetics of LY303366, a new lipopeptide an-tifungal agent related to echinocandin B, in female Lewis rats and beagle dogs. Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, 1993 Abstr. 370.
   Google Scholar
• Oral versus iv pharmacokinetic parameters for LY303366 and the phosphate ester prodrug, LY307853, show the absolute bioavailabil-ity to be 1.6% and 1.8% in rats and 4.3% and 4.5% in dogs, respectively. For '366, the terminal half-life in rats and dogs was 18.1 and 10.9 hours, respectively, while the half-life for '366 from the prodrug '853 was 22.4 and 10.7 hours in the two species, respectively.
   Google Scholar